EMPA-KIDNEY Trial Protocol

A multicentre international randomized parallel group double-blind placebo-controlled clinical trial of EMPAgliflozin once daily to assess cardio-renal outcomes in patients with chronic KIDNEY disease

Does inhibition of sodium-glucose co-transporter-2 with empagliflozin prevent kidney disease progression and cardiovascular death in patients with chronic kidney disease?

Selective inhibition of sodium-glucose co-transporter-2 (SGLT-2) with empagliflozin causes urinary glucose excretion and reduces hyperglycaemia, weight, plasma circulating volume and blood pressure. This has been shown to translate safely into reduced clinical risk from cardiovascular disease (particularly heart failure and cardiovascular death) in people with type 2 diabetes (T2D) and established cardiovascular disease. SGLT-2 inhibition with empagliflozin also reduces albuminuria and slows the annual decline in estimated glomerular filtration rate in people with T2D who still have preserved kidney function. The kidney effects may result from increased sodium delivery to the kidney’s macula densa, which in turn causes glomerular afferent arteriolar vasoconstriction and reduced intraglomerular pressure. Raised intraglomerular pressure is believed to be central to the “final common pathway” of disease progression in chronic kidney disease (CKD). Since SGLT-2 inhibition with empagliflozin also causes glycosuria and acute haemodynamic changes in kidney function in people without diabetes, empagliflozin may also be nephroprotective in conditions without ambient hyperglycaemia, which collectively account for 50 to 70% of patients with CKD worldwide. Patients with established CKD are at substantial risk of progressing to end-stage kidney disease despite the use of medical therapies, including renin-angiotensin system inhibition, so identifying new treatments to delay progression is a priority. Moreover, patients with CKD are at high risk of cardiovascular death and heart failure, which may also be reduced by empagliflozin.

A streamlined international trial

This randomized trial will compare empagliflozin 10 mg once daily versus matching placebo, given on top of standard of care, in around 6000 participants with established CKD, with or without diagnosed diabetes mellitus, who are being treated (where tolerated) with an appropriate dose of a renin-angiotensin system inhibitor. The study is event-driven, and will continue until the required number of primary outcomes has occurred. Follow-up will allow reliable assessment of the effects of empagliflozin on kidney disease progression or cardiovascular mortality, and other clinical outcomes. The study design is streamlined: extra work for collaborating doctors and hospitals will be kept to a minimum, and only essential information will be collected. The trial is focused on readily identifiable and important clinical outcomes. Participant reported information recorded by participant interview directly into bespoke computer systems and centrally measured creatinine are the main means of data collection.
Table of contents

1.1 DOES INHIBITION OF SODIUM-GLUCOSE CO-TRANSPORTER-2 (SGLT-2) WITH EMPAGLIFLOZIN PREVENT KIDNEY DISEASE PROGRESSION OR CARDIOVASCULAR DEATH IN PATIENTS WITH CHRONIC KIDNEY DISEASE (CKD)? ................................................................. 6

1.1.1 Substantial cardiovascular risk exists for CKD patients despite statin-based therapy and antihypertensive therapy ................................................................. 6

1.1.2 Empagliflozin reduces the risk of cardiovascular death in people with type 2 diabetes and established cardiovascular disease ................................................. 6

1.1.3 Substantial risk of kidney disease progression in people with CKD despite inhibition of the renin-angiotensin system ................................................................. 6

1.1.4 Empagliflozin may be nephroprotective in patients without diabetes ................................................................. 7

1.1.5 The safety of empagliflozin has been established in people with type 2 diabetes ................................................................. 8

2.1 STUDY AIMS .................................................................................. 9

2.2 TREATMENT COMPARISONS .......................................................... 9

2.2.1 Run-in period prior to randomization ............................................. 9

2.2.2 Randomization to empagliflozin versus placebo .................................. 9

2.3 DATA ANALYSIS PLAN .................................................................. 10

2.3.1 Main and subsidiary assessments .................................................... 10

2.3.1.1 Primary assessment .................................................................. 10

2.3.1.2 Secondary assessments ............................................................. 10

2.3.1.3 Tertiary efficacy assessments .................................................... 11

2.3.2 Safety, biochemical and exploratory assessments ............................ 12

2.3.2.1 Safety assessments .................................................................. 12

2.3.2.2 Biochemical assessments .......................................................... 12

2.3.2.3 Exploratory assessments ........................................................... 13

2.3.2.4 Health economic assessments ................................................... 13

2.3.3 Statistical analysis ...................................................................... 13

2.4 SAMPLE SIZE AND PREDICTED NUMBER OF EVENTS .................. 14

2.4.1 Initial assumptions (prior to study start) ......................................... 14

2.4.1.1 Anticipated effects of empagliflozin on the primary outcome .......... 14

2.4.1.2 Planned study duration and statistical power ............................... 14

2.5 DATA AND SAFETY MONITORING .............................................. 15

2.5.1 Recording and reporting of adverse events ..................................... 15

2.5.1.1 Recording of Adverse Events (AEs) .......................................... 14

2.5.1.2 Recording and review of relevant AEs by LCC staff ..................... 15

2.5.1.3 Collection of Additional Information for Suspected Serious Adverse Reactions (SSARs) by CCO ................................................................. 17

2.5.1.4 Expedited reporting of SUSARs and exemptions from expedited reporting ................................................................. 17

2.5.2 Interim analyses: role of the independent Data Monitoring Committee ................................................................. 18

2.5.2.1 Regular unblinded analyses by the DMC .................................... 18

2.5.2.2 Early stopping for benefit ....................................................... 18

2.6 CENTRAL AND REGIONAL COORDINATION OF LOCAL CLINICAL CENTRES ................................................................. 19

2.6.1 Training and quality assurance ...................................................... 19

2.6.2 Supply of study treatment ............................................................ 20

2.6.3 Data management ...................................................................... 20

2.6.4 Biological sample assay, transport and storage .............................. 21

2.6.4.1 Local analysis of eligibility and safety bloods ............................. 21

2.6.4.2 Central assessment of samples collected at the randomization visit and during follow-up ................................................................. 21

2.6.4.3 Consent approval for unspecified analyses on blood and urine samples ................................................................. 21

2.6.5 Administrative details .................................................................. 22

2.6.5.1 Source documents and archiving .............................................. 22

2.6.5.2 Funding ................................................................................ 22

2.6.5.3 Indemnity .............................................................................. 22

2.6.5.4 End of the within-trial period .................................................. 22

2.6.5.5 Publications and reports .......................................................... 22

2.6.5.6 Substudies ............................................................................ 23

3.1 ELIGIBILITY FOR THE STUDY ............................................... 25

3.1.1 Inclusion criteria ...................................................................... 25

3.1.2 Exclusion criteria ..................................................................... 25

3.2 IDENTIFICATION AND INVITATION ........................................ 26

3.2.1 Identification and invitation of potentially eligible participants .......... 26

3.3 SCREENING VISIT AND PRE-RANDOMIZATION RUN-IN. ............ 26

3.3.1 Assessment of relevant medical history and eligibility .................... 26

3.3.2 Written consent ...................................................................... 26

3.3.3 Confirmation of eligibility and collection of blood and urine samples ................................................................. 27

3.3.4 Review of eligibility and renin-angiotensin system inhibition by a Local Investigator ................................................................. 27

3.4 RANDOMIZATION VISIT (0 MONTHS) ........................................ 28
3.4.1 Final check of eligibility and compliance before randomization ............................................. 28
  3.4.1.1 Collection of blood and urine samples ........................................................................ 28
  3.4.2 Random allocation of study treatment ........................................................................... 28

3.5 FOLLOW-UP VISITS (2 AND 6 MONTHS AND THEN 6-MONTHLY) ........................................... 29
  3.5.1 Recording adverse events and adherence to study treatment ........................................... 29
  3.5.2 Collection of blood and urine samples ........................................................................... 29
  3.5.3 Issuing study treatment and arranging further appointments ........................................... 30
  3.5.4 Follow-up for randomized participants not attending study clinics .................................. 30
  3.5.5 Monitoring of women of child bearing potential ............................................................. 30
  3.5.6 Monitoring of people with diabetes mellitus ................................................................... 30
  3.5.7 Local Lead Investigator supervision .............................................................................. 31

3.6 CENTRAL MONITORING OF PARTICIPANT SAFETY, EARLY RECALL VISITS AND MODIFYING STUDY TREATMENT .......................................................... 31
  3.6.1 Early Recall Visits ........................................................................................................... 31
  3.6.2 Monitoring liver function, potassium, creatinine and AESIs .......................................... 31
  3.6.3 Modifying study treatment ............................................................................................ 31
  3.6.4 Unblinding of study treatment ....................................................................................... 32
  3.6.5 Withdrawal of consent .................................................................................................. 32

3.7 CONFIRMATION AND VERIFICATION OF STUDY OUTCOMES ("ADJUDICATION") .................. 32

3.8 CITED REFERENCES ............................................................................................................. 33

4.1 APPENDIX 1: ORGANISATIONAL STRUCTURE AND RESPONSIBILITIES FOR STUDY DESIGN AND CONDUCT .................................................................................. 37

4.2 APPENDIX 2: VISIT SCHEDULE AND PROCEDURES ................................................................ 40
  4.2.1 Clinic procedures ............................................................................................................ 40

4.3 APPENDIX 3: STUDY ADDRESSES ...................................................................................... 41

5.1 VERSION HISTORY ............................................................................................................... 42
### TRIAL SYNOPSIS

<table>
<thead>
<tr>
<th>Trial title</th>
<th>A multicentre international randomized parallel group double-blind placebo-controlled clinical trial of EMPAaglifluzin once daily to assess cardio-renal outcomes in patients with chronic KDNEY disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Short and lay title</td>
<td>EMPA-KIDNEY (The study of heart and kidney protection with empagliflozin)</td>
</tr>
<tr>
<td>Clinical phase</td>
<td>III</td>
</tr>
<tr>
<td>Trial design</td>
<td>Randomized double-blind placebo-controlled trial</td>
</tr>
<tr>
<td>Responsibilities</td>
<td>The study was initiated by the University of Oxford and developed in a collaboration with Boehringer Ingelheim, which has provided funding for the trial. Boehringer Ingelheim, the sponsor of this trial, has delegated responsibility for the conduct, analysis and reporting of the trial to the University of Oxford.</td>
</tr>
<tr>
<td>Boehringer Ingelheim ID</td>
<td>1245-0137</td>
</tr>
<tr>
<td>ClinicalTrials.gov</td>
<td>NCT03594110</td>
</tr>
<tr>
<td>EudraCT number</td>
<td>2017-002971-24</td>
</tr>
<tr>
<td><strong>Trial participants</strong></td>
<td>Eligibility criteria:</td>
</tr>
<tr>
<td></td>
<td>1. Aged ≥18 years at Screening; and</td>
</tr>
<tr>
<td></td>
<td>2. Chronic kidney disease (CKD) at risk of kidney disease progression;†</td>
</tr>
<tr>
<td></td>
<td>3. A local investigator judges that the participant neither requires empagliflozin (or any other SGLT-2 or SGLT-1/2 inhibitor), nor that such treatment is definitely inappropriate; and</td>
</tr>
<tr>
<td></td>
<td>4. No exclusion criteria apply</td>
</tr>
<tr>
<td></td>
<td>Participants will be treated with appropriate doses of renin-angiotensin system (RAS)-inhibition, unless such treatment is either not tolerated or not indicated. No patient currently being treated with empagliflozin (or other SGLT-2 or SGLT-1/2 inhibitor) should be taken off this therapy to meet the eligibility criteria. Throughout the study, the care of participants will remain the responsibility of their local doctors who will be asked to ensure individualized standards of care, including management of cardiovascular risk factors and other existing comorbidities (e.g. hypertension, diabetes etc.). This should be conducted in the context of prevailing local, national or international guidance.</td>
</tr>
<tr>
<td>Planned sample size</td>
<td>Approximately 6000 participants, including at least one-third with diabetes, one-third without diabetes, and up to one-third with a CKD-EPI estimated glomerular filtration rate (eGFR) ≥45 and &lt;90 mL/min/1.73m² at Screening</td>
</tr>
<tr>
<td>Placebo Run-in</td>
<td>8-12 weeks</td>
</tr>
<tr>
<td>Treatment duration</td>
<td>Event driven: the trial will continue until at least 1070 participants have experienced a first primary outcome after randomization</td>
</tr>
<tr>
<td>Primary outcome</td>
<td>Time to first occurrence of:</td>
</tr>
<tr>
<td></td>
<td>• Kidney disease progression (end-stage kidney disease, a sustained eGFR &lt;10 mL/min/1.73m², renal death, or a sustained ≥40% decline in eGFR from randomization) or</td>
</tr>
<tr>
<td></td>
<td>• Cardiovascular death</td>
</tr>
<tr>
<td>Secondary outcomes</td>
<td>Key secondary outcomes:</td>
</tr>
<tr>
<td></td>
<td>• Time to first hospitalization for heart failure or cardiovascular death</td>
</tr>
<tr>
<td></td>
<td>• Time to occurrences of all-cause hospitalization (first and recurrent combined)</td>
</tr>
<tr>
<td></td>
<td>• Time to death from any cause</td>
</tr>
<tr>
<td></td>
<td>Other secondary outcomes:</td>
</tr>
<tr>
<td></td>
<td>• Time to kidney disease progression</td>
</tr>
<tr>
<td></td>
<td>• Time to cardiovascular death</td>
</tr>
<tr>
<td></td>
<td>• Time to cardiovascular death or end-stage kidney disease</td>
</tr>
<tr>
<td>Medicinal Product</td>
<td>Oral empagliflozin 10 mg</td>
</tr>
<tr>
<td>Formulation, dose, route of administration</td>
<td>Run-in: placebo film-coated tablet once daily (single-blind) for oral administration; From randomization: empagliflozin 10 mg film-coated tablet once daily versus matching placebo film-coated tablet once daily (double-blind) for oral administration</td>
</tr>
</tbody>
</table>

* Or “full age” as required by local regulations (e.g. 20 years in Japan)
† Either (i) estimated glomerular filtration rate (eGFR) ≥20, <45 mL/min/1.73m²; or (ii) eGFR ≥45, <90 mL/min/1.73m² with urine albumin:creatinine ratio ≥200 mg/g
‡ End-stage kidney disease is defined as the initiation of maintenance dialysis or receipt of a kidney transplant
## PROTOCOL ABBREVIATIONS AND GLOSSARY

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALT/AST</td>
<td>Alanine/Aspartate Transaminase</td>
<td>Liver transaminases</td>
</tr>
<tr>
<td>AE/ AESI/ SAE/ SSAR/ SUSAR</td>
<td>Adverse Event/ Adverse Event of Specialist Interest/ Serious Adverse Event/ Suspected Serious Adverse Reaction/ Suspected Unexpected Serious Adverse Reaction</td>
<td></td>
</tr>
<tr>
<td>CCO</td>
<td>Central Coordinating Office</td>
<td>The Central Co-ordinating Office based at CTSU in Oxford, responsible for the overall coordination of the study</td>
</tr>
<tr>
<td>CCO study clinician</td>
<td>Central Coordinating Office study clinician</td>
<td>One of a group of CCO doctors responsible for monitoring the safety of participants through review of AEs and local laboratory results</td>
</tr>
<tr>
<td>CI</td>
<td>Confidence Interval</td>
<td></td>
</tr>
<tr>
<td>CKD</td>
<td>Chronic Kidney Disease</td>
<td></td>
</tr>
<tr>
<td>CTSU</td>
<td>Clinical Trial Service Unit and Epidemiological Studies Unit</td>
<td>Home of the CCO at the University of Oxford</td>
</tr>
<tr>
<td>DMC</td>
<td>Data Monitoring Committee</td>
<td></td>
</tr>
<tr>
<td>eGFR</td>
<td>Estimated Glomerular Filtration Rate</td>
<td></td>
</tr>
<tr>
<td>ESKD</td>
<td>End-Stage Kidney Disease</td>
<td></td>
</tr>
<tr>
<td>HbA1c</td>
<td>Glycated Haemoglobin</td>
<td></td>
</tr>
<tr>
<td>HR</td>
<td>Hazard Ratio</td>
<td></td>
</tr>
<tr>
<td>ICH-GCP</td>
<td>International Conference for the Harmonisation of Good Clinical Practice</td>
<td>Guidance for conducting clinical studies</td>
</tr>
<tr>
<td>IRB/REB</td>
<td>Institutional Review Board / Research Ethics Board</td>
<td></td>
</tr>
<tr>
<td>LCC</td>
<td>Local Clinical Centre</td>
<td></td>
</tr>
<tr>
<td>LCC clinic staff</td>
<td>Local Clinical Centre clinic staff</td>
<td>The LCC Research Coordinators and Local Investigators</td>
</tr>
<tr>
<td>LCC Research Coordinator</td>
<td>Local Clinical Centre Research Coordinator</td>
<td>The person(s) conducting the participant interviews, usually a qualified nurse, but in some cases may be medically qualified or have other relevant qualifications and experience. All individuals fulfilling this role will receive appropriate training organized by the RCC</td>
</tr>
<tr>
<td>Local doctor</td>
<td>Any doctor who has clinical responsibility for the care of the participants, including their primary care doctor or a hospital doctor</td>
<td></td>
</tr>
<tr>
<td>LLI</td>
<td>Local Lead Investigator</td>
<td>The doctor responsible for the trial at a LCC who is supported by other Local Investigators and LCC Research Co-ordinators (to whom certain trial-related activities are delegated).</td>
</tr>
<tr>
<td>MedDRA</td>
<td>Medical Dictionary for Drug Regulatory Activities</td>
<td></td>
</tr>
<tr>
<td>NT-proBNP</td>
<td>N-terminal Prohormone of Brain Natriuretic Peptide</td>
<td></td>
</tr>
<tr>
<td>PI</td>
<td>Principal Investigator</td>
<td>The grant holders for the study at the University of Oxford, who are collectively responsible for the conduct of the trial.</td>
</tr>
<tr>
<td>RAS-inhibitors (ACEi/ARB)</td>
<td>Renin-Angiotensin System inhibitors (Angiotensin-Converting Enzyme inhibitor/ Angiotensin Receptor Blocker)</td>
<td></td>
</tr>
<tr>
<td>RCC</td>
<td>Regional Coordinating Centre</td>
<td></td>
</tr>
<tr>
<td>SGLT</td>
<td>Sodium-Glucose Co-transporter</td>
<td></td>
</tr>
<tr>
<td>SOP</td>
<td>Standard Operating Procedure</td>
<td></td>
</tr>
<tr>
<td>T2D</td>
<td>Type 2 Diabetes</td>
<td></td>
</tr>
<tr>
<td>ULN</td>
<td>Upper Limit of Normal</td>
<td></td>
</tr>
<tr>
<td>WOCBP</td>
<td>Women of Child Bearing Potential</td>
<td></td>
</tr>
</tbody>
</table>
1.1 Does inhibition of sodium-glucose co-transporter-2 (SGLT-2) with empagliflozin prevent kidney disease progression or cardiovascular death in patients with chronic kidney disease (CKD)?

1.1.1 Substantial cardiovascular risk exists for CKD patients despite statin-based therapy and antihypertensive therapy

In high-income countries, the prevalence of CKD is about 10% and is likely to increase as average population age rises and diabetes mellitus becomes more prevalent.\(^1\)\(^2\) Cardiovascular risk increases progressively as kidney function declines.\(^3\)\(^4\) There is evidence that lowering low-density lipoprotein cholesterol and blood pressure in people with CKD reduces cardiovascular risk,\(^5\)\(^6\) but substantial residual risk remains and no other treatments have been shown to reduce cardiovascular risk in this group of patients.

A key feature of cardiovascular disease in CKD is presence of structural heart pathologies (e.g. left ventricular hypertrophy and/or dilatation) and heart failure (which may be accompanied by coronary heart disease). At least half of patients with advanced CKD (i.e. stages 4-5) have abnormal cardiac structure on echocardiography,\(^7\)\(^8\) increasing to over 80% by the time dialysis is initiated.\(^8\)

1.1.2 Empagliflozin reduces the risk of cardiovascular death in people with type 2 diabetes and established cardiovascular disease

Selective inhibition of SGLT-2 causes increased urinary glucose and transiently increased sodium excretion. This is associated with reductions in weight and blood pressure as well as haemoglobin glycation (HbA1c). Among 7020 patients with type 2 diabetes mellitus (T2D) and established cardiovascular disease in the EMPA-REG OUTCOME trial, empagliflozin reduced the primary cardiovascular composite outcome (death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke) by 14% compared to placebo (hazard ratio [HR] 0.86, 95% confidence interval [CI] 0.74-0.99). This was driven by a significant reduction in cardiovascular death (HR 0.62, 95% CI 0.49-0.77, nominal p<0.0001). A pre-specified secondary outcome of hospitalization for heart failure was reduced by 35% (HR 0.65, 95% CI 0.50-0.85).\(^9\)

The EMPA-REG OUTCOME trial was conducted in participants with relatively preserved kidney function (>90% had a baseline estimated glomerular filtration rate [eGFR] >45 mL/min/1.73m\(^2\)), and it is unclear whether empagliflozin can prevent cardiac disease in patients with more severe kidney impairment.

1.1.3 Substantial risk of kidney disease progression in people with CKD despite inhibition of the renin-angiotensin system

CKD is often a progressive condition, with proteinuria representing a significant risk factor for a more rapid decline in kidney function.\(^10\) Although patients with early CKD are more likely to die before they reach end-stage kidney disease (ESKD), the avoidance of ESKD is still highly desirable due to its adverse effects on quality of life and the substantial costs of dialysis and transplantation to healthcare providers. Inhibition of the renin-angiotensin system (RAS) with angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) reduces albuminuria and slows the rate of progression in proteinuric nephropathies, particularly in diabetic kidney disease.\(^11\)\(^-\)\(^13\) However, a substantial residual risk of ESKD remains. Although combination therapy (i.e. ACEI plus ARB) was initially thought to be a promising approach, such combined regimens do not delay kidney disease progression and may cause hyperkalaemia or acute kidney injury.\(^14\) There is therefore a
need for new treatments that can be added safely to current standard treatments in order to slow progression to ESKD.

SGLT-2 inhibition with empagliflozin shows the potential to reduce the risk of kidney disease progression in people with T2D. An exploratory analysis of the EMPA-REG OUTCOME trial indicated that empagliflozin reduced the incidence of the composite outcome of doubling of creatinine, the need to start kidney replacement therapy or renal death by 46% (HR 0.54, 95% CI 0.40-0.75). This nephroprotective effect occurred on the background of an initial decrease in eGFR over the first 4 weeks of treatment among those allocated to empagliflozin (Figure 1 from EMPA-REG OUTCOME below). The magnitude of the kidney effect associated with empagliflozin was consistent at doses of 10 mg and 25 mg (Figure 1), and across pre-specified subgroups of kidney function and parameters indicative of kidney damage, including patients with prevalent CKD (mainly early stage CKD). These benefits were similar regardless of baseline ACEi or ARB use and there was no evidence of an increased risk of hyperkalaemia or acute kidney injury. However, it is not possible to draw definite conclusions about the effects of SGLT-2 inhibition with empagliflozin in people with more established CKD (indeed, empagliflozin is currently not licensed for use in people with an eGFR <45 mL/min/1.73m²).

**Figure 1:** Change in eGFR in the EMPA-REG OUTCOME trial by treatment allocation

1.1.4 Empagliflozin may be nephroprotective in patients without diabetes

Experimental and clinical studies suggest that tubular dysregulation may drive kidney disease progression in a wide range of patients with advanced CKD. This dysregulation is characterized by excessive reabsorption of sodium in the early proximal tubule, mediating afferent arteriolar vasodilatation and, consequently, causing intraglomerular hypertension and associated glomerular barotrauma. In support of the hypothesis that intraglomerular hypertension is a final common pathway for progression for many forms of CKD, it has been observed that, for a given level of urinary albumin excretion, the risks of ESKD are relatively independent of the primary cause of kidney disease. The mechanisms behind the kidney effects of empagliflozin are likely multifactorial but direct kidney haemodynamic effects are considered to play an important role. Empagliflozin reduces proximal tubular sodium absorption...
reabsorption, thereby increasing distal sodium delivery to the macula densa, which has been shown to activate a tubulo-glomerular feedback leading to afferent arteriolar vasoconstriction, thereby reducing intraglomerular pressure and urinary albumin excretion.

Empagliflozin has also been shown to have a pharmacological effect in people without diabetes. In healthy volunteers, empagliflozin 10 mg daily resulted in approximately 50 g/day glycosuria, and an initial acute decrease in GFR (an indicator of reduced intraglomerular pressure) has been shown to occur in overweight but otherwise healthy volunteers (unpublished data, BI clinical trial report 1245.66). Taken together, these observations suggest that empagliflozin has haemodynamic effects in the kidney in the absence of elevated blood glucose.

It is therefore reasonable to hypothesize that empagliflozin may have beneficial effects on kidney disease progression and cardiovascular risk among those with CKD, irrespective of the presence of diabetes. Worldwide, the proportion of patients with CKD who have diabetes ranges from about 30 to 50% so, if empagliflozin has beneficial effects on kidney and cardiovascular outcomes in CKD, then its use in patients with CKD but without diabetes would increase the potential population who might benefit from this drug by 2-3 times,\textsuperscript{20, 21}

1.1.5 The safety of empagliflozin has been established in people with type 2 diabetes

The empagliflozin clinical development programme has randomized >15,000 trial participants to date. About 550 healthy volunteers have been exposed to empagliflozin (up to 800 mg in a single dose and up to 50 mg in multiple dosing), with good tolerability. Approximately 8500 patients with T2D have been treated with empagliflozin in clinical studies, of which more than half have been treated for a year or more.\textsuperscript{22-30} In all these studies, empagliflozin was well tolerated. In the EMPA-REG OUTCOME trial, which had a median follow-up of 3.1 years, the frequency of serious adverse events (SAEs) and adverse events that led to discontinuation of study treatment among patients allocated empagliflozin was no higher than that among those allocated placebo.\textsuperscript{9, 15} There was no significant increase in the frequency of hypoglycaemia with empagliflozin, except when used in combination with a sulphonylurea or basal dose insulin.\textsuperscript{31} Electrolytes were not significantly different among those allocated to empagliflozin or placebo.\textsuperscript{31} Compared to placebo, there was an increased frequency of mycotic genital infections. By contrast with the increased risk of bone fracture and lower-limb amputation observed with another SGLT-2 inhibitor, canagliflozin,\textsuperscript{32} there was no such adverse safety signal observed when over 12,000 patients with T2D from placebo-controlled empagliflozin clinical trials (including EMPA-REG OUTCOME) were analysed together.\textsuperscript{31} Further safety analyses from EMPA-REG OUTCOME showed that the adverse event profile of empagliflozin in patients who had impaired kidney function at baseline (i.e. eGFR <60 mL/min/1.73m\textsuperscript{2}), a potentially vulnerable population, was consistent with that reported in the overall trial population.\textsuperscript{15} In summary, the EMPA-KIDNEY trial aims to assess whether empagliflozin reduces the risk of kidney disease progression or cardiovascular death in people with CKD, irrespective of whether they have diabetes, and whether the benefits of treatment outweigh any adverse effects.
2.1 STUDY AIMS
The study will randomize approximately 6000 participants with pre-existing CKD (at least one-third with diabetes and one-third without diabetes) between empagliflozin 10 mg daily and matching placebo on top of standard of care. The trial will continue until a minimum number of 1070 primary outcomes has accrued (i.e. the trial is event-driven). The primary aim is to assess the effect of empagliflozin on time to kidney disease progression or cardiovascular death (see Section 2.3.1.1).

The key secondary aims are to assess the effect of empagliflozin on time to hospitalization for heart failure or cardiovascular death, occurrences of hospitalizations from any cause, and time to death from any cause (see Section 2.3.1.2). Other assessments, including analyses of safety, are also planned, and are described in Sections 2.3.1.2 to 2.3.2.4.

2.2 TREATMENT COMPARISONS
2.2.1 Run-in period prior to randomization
Prior to randomization, potentially eligible participants will enter an 8-12 week Run-in period, during which they will receive single-blind placebo tablets. The purpose of the Run-in period is to help ensure that only those likely to continue taking study treatment for an extended period are randomized (see Figure 2).

Information collected at the Screening Visit will be provided to Local Investigators, who will be asked to confirm that in their judgment the participant:

(i) Neither requires empagliflozin (or any other SGLT-2 or SGLT-1/2 inhibitor), nor that such treatment is definitely inappropriate; and

(ii) Has been prescribed an appropriate dose of a RAS-inhibitor, unless such treatment is either not tolerated or not indicated (see Section 3.3.4).

At Screening and throughout the study, the care of participants will remain the responsibility of local doctors who are asked to ensure individualized standard of care, including management of cardiovascular risk factors and other existing comorbidities (e.g. hypertension, diabetes etc.). It is advised that prevailing local, national or international guidance is considered (see Section 3.3.4).

2.2.2 Randomization to empagliflozin versus placebo
Eligible and consenting individuals will be allocated empagliflozin or placebo using a minimized randomization algorithm that helps ensure balance between the treatment groups with respect to the following prognostic variables: age, sex, prior diabetes, eGFR and urinary

---

Figure 2. Outline of 1:1 randomization and follow-up schedule
albumin:creatinine ratio (both based on local laboratory results at screening), and region. The algorithm includes a stochastic element (treatment is assigned to the arm determined by the minimization algorithm with a probability of 0.9 and by a random number generator with a probability of 0.1). Given the stochastic element of the randomization, rerandomization methods for the analysis are not considered necessary and only traditional methods of analysis are planned. Randomized participants will be issued with a 7-month supply of study treatment consisting of empagliflozin 10 mg or matching placebo. One tablet is to be taken daily with or without food. To ensure a dose interval of about 24 hours, the medication should ideally be taken at approximately the same time every day.

2.3 DATA ANALYSIS PLAN

2.3.1 Main and subsidiary assessments

2.3.1.1 Primary assessment

The primary assessment will involve an intention-to-treat comparison among all randomized participants, using a Cox model adjusting for each of the minimization variables (see above), of the effects of allocation to empagliflozin versus placebo on the time to the first occurrence of:

(i) Kidney disease progression (defined as ESKD, a sustained decline in eGFR to <10 mL/min/1.73m², renal death, or a sustained decline of ≥40% in eGFR from randomization); or
(ii) Cardiovascular death.

ESKD is defined as the initiation of maintenance dialysis or receipt of a kidney transplant.

To ensure bias is not introduced by differences between treatment arms in the extent to which extra eGFR measurements are made outside of scheduled follow-up visits, the term ‘sustained’ in respect of a decline in eGFR (to <10 mL/min/1.73m², or of ≥40% from baseline) is that it is either (a) measured at two consecutive scheduled study follow-up visits; or (b) measured at the last scheduled study follow-up visit or the last scheduled visit before death (or withdrawal of consent).

2.3.1.2 Secondary assessments

If the primary outcome is statistically significant (either at the interim or final analysis), the key secondary outcomes will then be tested. The secondary assessments will involve intention-to-treat comparisons among all randomized participants of the effects of allocation to empagliflozin versus placebo during the scheduled treatment period on:

(i) Key secondary outcomes:
   a) Time to first hospitalization for heart failure or cardiovascular death;
   b) Time to occurrences of all-cause hospitalizations (first and recurrent combined);
   c) Time to death from any cause.
(ii) Other secondary outcomes:
   a) Time to first occurrence of kidney disease progression;
   b) Time to cardiovascular death;
   c) Time to cardiovascular death or ESKD.

In testing the key secondary outcomes, their p-values will be corrected for multiple testing using the Hochberg “step-up” procedure that controls the familywise error rate. Other secondary outcomes will be assessed without adjustment for multiplicity at a nominal level of $\alpha = 0.05$ (two-sided).

2.3.1.3 Tertiary efficacy assessments
Tertiary assessments will involve intention-to-treat analyses among all randomized participants of the effects of allocation to empagliflozin versus placebo during the scheduled treatment period on:

2.3.1.3.1 Renal tertiary outcomes
(i) Time to components of kidney disease progression defined as follows:
   (a) ESKD, a sustained decline in eGFR to <10 mL/min/1.73m², or renal death;
   (b) Sustained decline of $\geq 40\%$ in eGFR from randomization;

(ii) Annual rate of change in eGFR, calculated separately:
   (a) For the whole follow-up period;
   (b) From 2 months until the last scheduled visit;

2.3.1.3.2 Mortality-based tertiary outcomes
(iii) Time to ESKD or death from any cause combined;

(iv) Time to kidney disease progression or death from any cause combined;

(v) Time to death from particular categories of causes, including cardiovascular (coronary death, other cardiac [including heart failure and sudden cardiac death not known to be coronary], stroke, other cardiovascular and presumed cardiovascular) and non-cardiovascular (e.g. renal, infection, cancer, other medical, and non-medical) causes;

2.3.1.3.3 Cardiovascular and metabolic tertiary outcomes
(vi) Time to major cardiovascular events (defined as the composite of cardiovascular death, myocardial infarction, stroke or hospitalization for heart failure);

(vii) Time to new-onset diabetes mellitus (defined as clinical diagnosis, commencement of glucose-lowering treatment, or HbA1c $\geq 48$ mmol/mol measured by central laboratory on at least one occasion) among participants without diabetes at baseline*, overall and separately among those with normoglycaemia or “pre-diabetes” (defined as HbA1c <39 mmol/mol [normoglycaemia] and $\geq 39$ to <48 mmol/mol [pre-diabetes], respectively);

(* diabetes at baseline is defined as participant-reported history of diabetes, use of glucose-lowering medication or baseline HbA1c $\geq 48$ mmol/mol at Randomization visit).

(viii) Time to self-reported episode of gout;

2.3.1.3.4 Subgroup analyses
(ix) Subgroup analyses are planned for the primary composite outcome;
Pre-specified categories for subgroup analyses are defined as follows:
- History of prior disease (presence vs. absence): diabetes mellitus; cardiovascular disease; heart failure; peripheral arterial disease;
- Age; sex; region; blood pressure; body mass index;
- Laboratory values: HbA1c; eGFR; urinary albumin:creatinine ratio; NT-proBNP; haematocrit (see Section 2.3.3 for approach to grouping);
- Medication: RAS-inhibition; beta-blocker; diuretics.

The subgroup analyses of the primary composite outcome which are of key interest are those involving subdivision by: (a) baseline diabetes status, (b) baseline eGFR, and (c) urinary albumin:creatinine ratio.

2.3.2 Safety, biochemical and exploratory assessments

2.3.2.1 Safety assessments
Safety assessments will involve intention-to-treat among all randomized participants and, where appropriate, on-treatment analyses of the effects of allocation to empagliflozin versus placebo during the scheduled treatment period on:

(i) SAEs due to:
(a) Urinary tract infection, overall and separately by sex;
(b) Genital infection, overall and separately by sex;
(c) Hyperkalaemia;
(d) Acute kidney injury;
(e) Dehydration;

(ii) AEs of Special Interest (AESIs):
(a) Liver injury, both overall and separately by cause (defined as ALT or AST ≥5x Upper Limit of Normal [ULN] or the combination of ALT or AST ≥3x ULN with bilirubin ≥2x ULN; measured in the same blood sample at study follow-up or early recall visits; see Section 3.5.2);
(b) Ketoacidosis, both overall and, separately, by baseline diabetes status;
(c) Lower limb amputations (overall and by level);

(iii) Other AEs relevant to the study question:
(a) Bone fractures, both overall and separately by site and aetiology (i.e. distinguishing those resulting from high and low impact trauma);
(b) Severe hypoglycaemia (defined as low blood sugar causing severe cognitive impairment which requires assistance from another person for recovery);
(c) Symptomatic dehydration (defined as whether or not a participant has experienced symptoms they attribute to dehydration, such as feeling faint or fainting);

(iv) Hospitalization by specific causes†;

(v) SAEs both overall and, separately, by category†;

(vi) Discontinuation of study treatment overall and by various causes (including SAEs†, non-serious adverse events†, and other reasons);

† based on Medical Dictionary for Drug Regulatory Activities (MedDRA) System Organ Class classification
Changes in weight and systolic and diastolic blood pressure from baseline.

2.3.2.2 Biochemical assessments
Additional biochemical assessments at the central laboratory on urine and blood (collected at the Randomization visit, 2 months, 18 months and the Final-follow-up visit) will involve intention-to-treat analyses among all randomized participants of the effects of allocation to empagliflozin versus placebo during the scheduled treatment period on:
- Urine albumin:creatinine ratio
- HbA1c.

Biochemical assessments using local laboratory results will involve intention-to-treat analyses among all randomized participants, and where appropriate, on-treatment analyses of the effects of allocation to empagliflozin versus placebo during the scheduled treatment period on:
- Potassium
- ALT/AST (including elevations of ALT/AST in various categories)
- Sodium, corrected calcium and phosphate (in a subset of about 20%)
- Haematocrit and haemoglobin (in a subset of about 20%).

2.3.2.3 Exploratory assessments
Exploratory assessments may also be made of other possible beneficial or adverse effects of empagliflozin, including secondary or tertiary outcomes by pre-specified subgroups, on mean eGFR at each scheduled visit and at the 4-week post-Final Follow-up blood draw (see Section 3.5.2), urine albumin:creatinine ratio 4 weeks after Final Follow-up, and how treatment effects vary by time since Randomization. In interpreting the results of any exploratory analyses that will be performed, allowance will be made for multiple hypothesis testing, their exploratory (and, perhaps, data-dependent) nature, and for evidence from other studies. Analyses of fatal events will be interpreted in the light of the observed effects on relevant non-fatal events.34

2.3.2.4 Health economic assessments
The study results may, if appropriate, be used to conduct health economic assessments regarding the use of empagliflozin. An analysis plan will be pre-specified if any such analyses are considered worthwhile.

2.3.3 Statistical analysis
A full Data Analysis Plan will be finalised prior to any unblinding of study results. Briefly, all participants randomized to empagliflozin will be compared with all participants randomized to placebo, regardless of whether a participant received all, some or none of their allocated treatment (i.e. intention-to-treat analyses). A participant may contribute to more than one assessment if they have events of more than one type (e.g. hospitalization for heart failure followed by ESKD). For the time-to-event analyses survival analytic methods will be used to evaluate the time to the first event during the entire study period. For each categorical outcome, Cox proportional hazards regression adjusted for the prognostic variables used in the minimization algorithm (age, sex, prior diabetes, eGFR, urinary albumin:creatinine ratio, and region) will be used to estimate the hazard ratio comparing all those allocated active empagliflozin with all those allocated placebo. Estimates of the hazard ratio will be shown with 95% confidence intervals, and Kaplan-Meier estimates for the time to each of the primary and secondary outcomes will also be plotted. For the secondary outcome of all-cause hospitalization, the analysis will examine all events (i.e. not just the first event in each participant).
Tests for heterogeneity of the proportional effect observed in subgroups, through the inclusion of relevant interaction terms in Cox models, will be used to determine whether the proportional effects in specific subcategories are clearly different from the overall effect. Where categories can be arranged in a meaningful order (e.g. age at randomization) then assessment of any trend will be made. For subgroups based on continuous variables (e.g. blood pressure), participants will be subdivided into approximately equal thirds based on the tertiles of the relevant distribution or, where appropriate, by conventional thresholds. Details of the sub-group classifications will be described in the Data Analysis Plan.

For analyses of continuous variables, such as blood pressure and analyses of biochemical effects (see Section 2.3.2.2), differences in means between the randomized groups will be assessed (after appropriate transformation, where necessary).

The more detailed Data Analysis Plan will provide methods for recurrent event analyses, planned sensitivity analyses (including the plotting of cumulative incidence functions), handling of model covariates and missing data, censoring rules and alternative methods of analysis for situations where there are issues with the fit of the main analysis model.

2.4 SAMPLE SIZE AND PREDICTED NUMBER OF EVENTS
2.4.1 Initial assumptions (prior to study start)

2.4.1.1 Anticipated effects of empagliflozin on the primary outcome
Whilst the EMPA-REG OUTCOME trial was conducted exclusively among people with T2D, it is anticipated that EMPA-KIDNEY will include a substantial proportion of participants without diabetes (at least one third), who are expected to experience smaller changes in glycosuria than those with diabetes (see Section 1.1.4). Since smaller changes in glycosuria in participants without diabetes may translate into smaller relative effects than in those with diabetes, it has been assumed that the relative reductions for both components of the primary outcome (i.e. cardiovascular death and kidney disease progression) in EMPA-KIDNEY will be about half as large as was observed in EMPA-REG OUTCOME.

2.4.1.2 Planned study duration and statistical power
The trial will randomize approximately 6000 participants from about 200-250 sites and continue until a minimum of 1070 primary outcome events has occurred. Such an event-driven trial would provide an overall power of 90% at p=0.05 (two-sided) to detect an 18% relative reduction in the primary outcome (time to kidney disease progression or cardiovascular death). During the trial, the Steering Committee will monitor event rates for the primary outcome and its components blind to treatment allocation, and if necessary, may consider proposing changes to the protocol. A formal interim analysis may be performed after 150 ESKD events have occurred (see Section 2.5.2.2 for details).

2.5 DATA AND SAFETY MONITORING
2.5.1 Recording and reporting of adverse events

2.5.1.1 Recording of Adverse Events (AEs)
The trial focuses on important clinical outcomes and is reliant upon both participant reported information and centrally measured kidney function as the primary means of data collection. It is not expected or required that medical records will be reviewed by Local Clinical Centre (LCC) clinic staff or monitoring staff to identify AEs, SAEs or other trial outcomes since the participants will be used as the primary source of information. Procedures for central adjudication of potential study outcomes are described in Section 3.7.
The safety profile of empagliflozin has been well-studied in previous trials. Therefore, in line with regulatory guidance, collection of safety data will be streamlined.

2.5.1.1 Non-serious adverse events
Non-serious AEs will only be recorded if they:
(a) Lead to discontinuation of study treatment; or
(b) Are one of the following:
  - Bone fracture (with additional information recorded about fracture site and aetiology [i.e. distinguishing those resulting from high and low impact])
  - Severe hypoglycaemia (as defined in Section 2.3.2.1)
  - Episodes of gout
  - Symptomatic dehydration (as defined in Section 2.3.2.1)
  - An Adverse Event of Special Interest (AESI; see Section 2.5.1.1.2)
  - Events that could lead to amputation (which include diagnosis or treatment for peripheral arterial disease, peripheral neuropathy, diabetic foot ulcer, and lower limb infection or gangrene).

2.5.1.1.2 Adverse Events of Special Interest (AESI)
The following AEs will be recorded regardless of whether they fulfil the criteria for a SAE:
  - Liver injury
  - Ketoacidosis
  - Lower limb amputations (overall and by level).

All new AESIs will be reviewed each working day by Central Co-ordinating Centre (CCO) clinicians and relevant additional details sought promptly (see Section 3.6.2). Detailed reports on AESIs will be provided by the CCO to Boehringer Ingelheim at regular intervals.

2.5.1.1.3 Serious Adverse Events (SAEs)
SAEs are defined as those adverse events that:
  - Result in death
  - Are life-threatening
  - Require inpatient hospitalization or prolongation of existing hospitalization;
  - Result in persistent or significant disability or incapacity
  - Result in congenital anomaly or birth defect
  - Are important medical events in the opinion of a responsible Local Investigator (i.e. not life-threatening or resulting in hospitalization, but may jeopardise the participant or require intervention to prevent one or other of the outcomes listed above).

For the purposes of this trial, certain pre-specified Preferred Terms (e.g. “agranulocytosis”, “interstitial lung disease”), and all cancers will always be considered Serious.

Pregnancy will not be considered an AE in this trial, but must be reported promptly (within 24 hours) to the Regional Co-ordinating Centre (RCC) or CCO and then followed up using Pregnancy Monitoring Forms.

2.5.1.2 Recording and review of relevant AEs by LCC staff
All relevant AEs (as defined in Section 2.5.1.1) reported by participants at each study visit interview will be recorded and assessed by trained LCC clinic staff (usually the LCC Research Coordinator) directly on the study computer-based data entry system (see Section

---

*a* In accordance with the European Medicines Agency initiative on Important Medical Events.

Note: New cancer diagnosis and recurrence of pre-existing cancer should all be recorded.
2.6.3), regardless of whether the participant continues to take study treatment or not. If the study team become aware of SAEs or AESIs between study visits, they are requested to report them within 24 hours. If LCC clinic staff cannot access the computer-based data entry system, they must contact their RCC to report the AE within that timeframe. After completion of the trial, investigators do not need to actively monitor participants, but could report SSARs or related AESIs through telephone contact to the RCC or CCO.

The electronic SAE form will capture the following information for all SAEs:
- Unique study identification number of the participant
- Unique SAE form identification number
- The time and date that the SAE form is completed
- The source of the report (e.g. participant, relative, study nurse, Local Investigator, or other doctor)
- A description of the event: Event descriptions will be recorded by the trained clinic staff using MedDRA Preferred Terms. If an appropriate term cannot be identified, advice can be sought from the Local Investigator or a CCO study clinician, or the description can be recorded as free-text and subsequently coded by CCO study clinician, blind to study treatment allocation
- The reason for believing the AE to be serious (i.e. resulted in death, life-threatening, hospitalisation, disabling, congenital anomaly in offspring, other important medical event)
- The date the event started
- The place where the event was diagnosed or managed (e.g. hospital inpatient, hospital outpatient, participant’s home)
- The name of the place where the event was diagnosed or managed (if appropriate)
- Number of nights spent in hospital (if applicable)
- The outcome (ongoing, recovered, death, unknown)
- Whether the event is thought likely to be due to study treatment. In making this assessment, there should be consideration, based on the available information, of the pharmacology of the drug and drug class, probability of an alternative cause, the timing of the reaction with respect to study drug, the response to withdrawal of the study drug, and (where appropriate) the response to subsequent re-challenge or dose change.

Such detailed information will also be collected for all AESIs.

The electronic non-serious AE form will capture the following information:
- Unique study identification number of the participant
- Unique AE form identification number
- The time and date that the AE form is completed
- A description of the event (as describe above)
- The date the event started
- The outcome (ongoing, recovered, unknown)
- Whether the event is thought likely to be due to study treatment (as above).

Local Investigators are required to review all AEs recorded by those LCC Research Coordinators who have been delegated the task of recording AEs.
2.5.1.3 Collection of Additional Information for Suspected Serious Adverse Reactions (SSARs) by CCO

Any SAE that is considered, with reasonable possibility, to be due to study treatment by either Local Investigators, appropriately delegated LCC clinic staff or CCO study clinicians (or Boehringer Ingelheim staff), is potentially a SSAR. The CCO study clinician will obtain standard information, including participant study number, identity of reporting person, description of event, and reason for attribution to study drug. All such reports will then be forwarded urgently to a CCO Clinical Coordinator (or their delegated CCO study clinician deputy), who will review the evidence for seriousness and relatedness (in discussion with the LLI if necessary), and seek any additional information required (including relevant information relating to medical history and treatment both prior to and following randomization, and prior to/at the time of onset of the SSAR).

2.5.1.4 Expedited reporting of SUSARs and exemptions from expedited reporting

SSARs that are unexpected according to the Investigator’s Brochure are subject to expedited reporting. However, in line with recommendations by regulatory authorities, anticipated events that either are efficacy endpoints, consequences of the underlying disease or are events common in the study population will be exempted from expedited reporting in order to protect trial integrity and because based on a single case it is not possible to conclude that there is a reasonable possibility that the investigational drug caused the event. Such events that are exempted from expedited reporting to health authorities in this trial are listed below.

1. Efficacy endpoints:
   - Kidney disease progression (i.e. ESKD)
   - Myocardial infarction
   - Stroke and transient ischaemic attack
   - Heart failure
   - CV death
   - New-onset diabetes mellitus.

2. Common CKD-related events:
   - Acute-on-chronic kidney failure
   - Dialysis and dialysis access related events and complications
   - Bone fractures and parathyroid-related events.

Any SSARs that are considered not exempt will be reported promptly by the CCO to Boehringer Ingelheim, and Boehringer Ingelheim will make an assessment of whether the event is “expected” or not (based on the latest version of the empagliflozin Investigator Brochure). Any SSAR that is unexpected will be considered a potential Suspected Unexpected Serious Adverse Reaction (SUSAR) and will be unblinded by a member of the CCO clinical staff with such privilege.

All SUSARs will be reported to relevant regulatory authorities, to the Chair of the Data Monitoring Committee (DMC) and, as required, to ethics committees and Institutional Review Boards and investigators in an expedited manner in accordance with regulatory requirements.

---

b The relevant MedDRA Preferred Terms which are exempt are specified in the Adverse Event Reporting SOP.
2.5.2 Interim analyses: role of the independent Data Monitoring Committee

2.5.2.1 Regular unblinded analyses by the DMC

The DMC will assess participant safety and the progress of the trial through review of unblinded data at specified intervals, and recommend to the Steering Committee and Boehringer Ingelheim whether to continue, modify, or stop the trial. Measures are in place to ensure blinding of Boehringer Ingelheim, University of Oxford, the Steering Committee and all other trial staff and participants. The tasks and responsibilities of the DMC will be specified in the DMC charter. The DMC will maintain written records of all its meetings.

The DMC will request analyses at a frequency relevant to the stage of the study (typically at 6-12 monthly intervals, with a Chair’s review every 3-6 months) or in response to emerging data from other trials. These unblinded analyses of all SAEs and other study outcomes (both overall and in key subgroups, including by region) and all expected SSARs will be supplied in strict confidence by a statistician not otherwise involved in the trial.

The DMC would be expected to advise the Steering Committee if clear evidence emerged of an adverse effect on all-cause mortality (at least 2 standard deviations) or if, in the view of the DMC, there was other compelling evidence of hazard that seemed likely to outweigh any potential benefit.

Unless advised by the DMC in response to clear evidence of hazard, the Steering Committee, collaborators, participants, representatives of the Boehringer Ingelheim, and all study staff will remain blind to these results until the end of the study. The DMC is independent of the University of Oxford and Boehringer Ingelheim.

2.5.2.2 Early stopping for benefit

In addition, the DMC may review a single formal interim efficacy analysis once 150 participants have experienced a first ESKD event (by which time it is expected that approximately 60% of all first primary outcomes will have occurred). Full details of the stopping guidelines at this interim analysis, including the alpha spent at this analysis and the alpha remaining for the final analysis, will be provided in the DMC Charter. Separate alpha-spending functions will be used for the testing of the primary and key secondary outcomes to control the type I error rate across two analysis time-points, and a gatekeeping approach followed by the Hochberg procedure will be used to control the type I error rate across multiple endpoints.

Briefly, in order for the DMC to recommend that the trial is stopped early for benefit at this formal interim analysis, both of the following conditions must be met:

1. A reduction in the primary outcome with the Hwang-Shih-DeCani alpha-spending function (γ=-8) used to define the required two-sided p-value and its corresponding critical Cox hazard ratio; and
2. A reduction in the secondary composite outcome of time to cardiovascular death or ESKD to at least the same critical Cox hazard ratio as observed in the primary outcome, but with the proviso that the p-value is constrained to be < 0.05. For example, for the scenario when 60% of the first primary outcomes (i.e. 642 first primary outcomes) have occurred at the time of the interim analysis, this would equate to stopping criteria of: (i) a two-sided p-value <0.002 with a critical Cox hazard ratio <0.78 for the primary outcome; and (ii) a critical Cox hazard ratio of <0.78 and a two-sided p-value <0.05 for the secondary outcome of time to cardiovascular death or ESKD [with 400 such events and a critical Cox hazard ratio of <0.78 a p-value of <0.014 would be observed]. Note the secondary outcome of time to cardiovascular death or ESKD is not part of the prospectively defined hypothesis testing strategy but is included as an additional stopping criterion to
ensure the trial is only stopped early if there is also substantial evidence of efficacy in this endpoint.

If these criteria are met, the key secondary outcomes will be formally analysed via the Hochberg procedure with the familywise error rate controlled at 3.0% (as per the Hwang-Shih-DeCani alpha-spending function, γ=0). If the trial is not stopped at the formal interim analysis, it will continue as planned until a minimum of 1070 participants have experienced the primary outcome, and the final two-sided p-value for the primary outcome would need to be <0.0497 to be deemed statistically significant. If statistically significant the Hochberg procedure with the familywise error rate controlled at 3.1% would be used for the key secondary outcomes. Note that if the proportion of first primary outcome events available at the interim analysis is not equal to 60% (information fraction used for both alpha-spending functions), then the p-values and critical hazard ratios at the interim/final analysis for the primary and key secondary outcomes will be adjusted accordingly (detailed separately, i.e. in the trial's DMC Charter). If this interim analysis is not considered appropriate (due to operational reasons, for example) then the alpha-level for the final analysis will be adjusted accordingly. No interim analysis for futility is planned.

2.6 CENTRAL AND REGIONAL COORDINATION OF LOCAL CLINICAL CENTRES

The Study will be coordinated by the CCO, based at the Medical Research Council Population Health Research Unit, which is part of the Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU) at the University of Oxford. The CCO will oversee RCCs which will assist with selection of LCCs within their region and for the administrative support and monitoring of those LCCs. At each LCC, a Local Lead Investigator and LCC Research Coordinator (usually a qualified nurse, but in some cases may be medically qualified or have other relevant qualifications and experience) will be responsible for identification, recruitment, and follow-up (see Appendix 1: Organisational Structure and Responsibilities). It is intended that approximately 6000 participants will be randomized at about 200-250 LCCs worldwide.

2.6.1 Training and quality assurance

The study will be conducted in accordance with the principles of International Conference on Harmonisation Guidelines for Good Clinical Research Practice (ICH-GCP) and relevant local, national and international regulations (including the EU Clinical Trial Directive and the US Code of Federal Regulations Chapter 21). Prior to initiation of the study at any LCC, the RCC will confirm that the LCC has adequate facilities and resources to carry out the study (and, if considered necessary, a site visit will be undertaken). LLI and LCC Research Coordinators will be provided with materials detailing relevant study procedures and receive standardized training in study methods, including how to perform interviews, code using MedDRA, ensure appropriate levels of investigator support and oversight, and use the bespoke computer-based study management systems (see Section 2.6.3). Training will include information about empagliflozin, including the potential for ketoacidosis to present without excessive hyperglycaemia whilst treated with SGLT-2 inhibition. Full details are provided in the study-specific Training Standard Operating Procedure (SOP).

The study will use Quality-by-Design approaches to prospectively build quality into the study design and operations rather than relying on retrospective monitoring. The focus will therefore be on those factors that are critical-to-quality (the protection of the participants and reliability of the trial results) rather than on the accuracy of individual data points. The Steering Committee will be responsible for reviewing study quality and risk-based management approaches and ensuring that the focus is always on issues that have (or the
potential to have) a substantial impact on the protection of the study participants or the reliability of the study results (with full details provided in a Quality Assurance Systems SOP).

Throughout the study, the CCO will centrally monitor performance against the predefined critical-to-quality factors. This process will predominantly be quantitative in nature and remedial actions will be determined based on the detection of deviations and totality of the evidence.

The relevant RCC and/or the CCO will arrange monitoring visits to LCCs as considered appropriate based on perceived training needs and the results of central process monitoring and statistical monitoring of study data (i.e. monitoring visits will be spaced by several months). The purpose of such visits will be to ensure that the study is conducted according to the protocol, ICH-GCP, and the applicable regulatory requirements, and by helping LCC clinic staff to resolve any local issues with the study and by providing additional focused training where necessary. Particular attention will be given to the effectiveness of strategies to recruit appropriate participants, the consenting process, the completeness of follow-up, the maintenance of participant compliance with the study treatments (which will be assessed by participant self-report), the reporting of study outcomes and reportable AEs (see Section 2.5.1), and collection of relevant supporting documentation to support the adjudication process (see Section 3.7). With the exception of local laboratory results (where a random subset will be assessed), no routine source data review and verification will take place as such data are obtained directly from participants (or occasionally from relatives or doctors) by interview. Where possible, monitoring visits will include observation of a participant’s study visit. A report of each monitoring visit will be prepared by the study monitor and provided to LCC, RCC and CCO staff (including the Head of Monitoring) for review, and filed appropriately. Copies of these reports will be supplied to Boehringer Ingelheim on request. With prior arrangement, representatives of Boehringer Ingelheim may attend monitoring visits. Details of monitoring are provided in an On-Site Monitoring SOP.

2.6.2 Supply of study treatment

Study treatments will be manufactured, packaged, labelled and delivered to each LCC or RCC by Boehringer Ingelheim (or their subcontractor) under the direction of the CCO and according to Good Manufacturing Practices. An inventory of study drug supplies will be maintained on the study computer-based system and monitored at the CCO. Local Investigators will be responsible for making appropriate arrangements for the storage and issuing of study treatments, and for the disposal of unused study drug in accordance with study SOPs.

2.6.3 Data management

All data in the study will be processed electronically using a set of custom-written applications developed to meet the requirements of the protocol and to comply with 21 CFR Part 11 and other relevant regulatory, legal and information security requirements. The LCC staff (usually the LCC Research Coordinator) will use bespoke web-based applications for local study management and to enter participant data (including study visit forms and AE information) directly into the database. These source data will be held in central databases located both at the CCO and at an independent third party where it will remain under the control of the Local Investigators (i.e. no paper case report forms exist). Any data queries reported by LCCs to the CCO or RCC (as per regional arrangements) during the study will be recorded onto the computer-based study management system. Data queries will be reviewed and managed by the CCO in accordance with an Internal Operating Procedure,
with data changes only made to pre-defined critical-to-quality data points. Clear electronic documentation will be maintained so the original data entry is not obscured and there is an audit trail for each entered data error and data change.

RCC and CCO staff will use the suite of administration applications on the computer-based system to manage LCCs and study participants, including central clinical supervision (review of AEs and laboratory results) by the CCO, management of follow-up and compliance, tracking of samples for central analysis, collection of supporting documentation for relevant events, and clinical outcome adjudication.

All data accesses will require a unique username and password, and any changes to data will require the user to enter their username and password as an electronic signature. Staff will have access restricted to only the functionality and data that are appropriate to their role in the study.

2.6.4 Biological sample assay, transport and storage

2.6.4.1 Local analysis of eligibility and safety bloods
Local laboratories will be used in all LCC study clinics for eligibility checks at the Screening visit (urine albumin:creatinine ratio [or protein:creatinine ratio, according to local practice], and blood creatinine plus liver transaminases [AST or ALT]), at the Randomization visit (blood creatinine, potassium, liver transaminases, bilirubin and haematocrit) and for clinical safety oversight at each follow-up visit (including blood creatinine, potassium and liver transaminases with bilirubin; see Section 4.2.1).

Haematocrit, haemoglobin, phosphate, sodium and corrected calcium will also be measured locally at 18 months of follow-up in a subset of about 20% (e.g. UK participants) of the surviving population.

2.6.4.2 Central assessment of samples collected at the randomization visit and during follow-up
Samples of both blood and urine are to be collected from all participants at the Randomization visit for central analysis and storage, including subsequent DNA extraction (subject to relevant consent, see Section 2.6.4.3) at a central ISO 17025 accredited laboratory. Central samples will not be used to assess eligibility. Further samples of both blood and urine are to be collected from all participants at the 2 month, 18 month (i.e. the approximate study midpoint) and Final Follow-up visits. Blood will be collected for central analysis of creatinine at the time of every scheduled Follow-up visit (see Section 4.2.1). RCCs will supply LCC staff with kits to collect these blood and urine samples. Blood is to be kept cool before centrifugation, separation into bar-coded cryovials, and storage at below -18°C within a day of the study clinic visit. Samples are to be transferred to below -40°C within 4 weeks. At appropriate intervals, samples will be collected from the LCCs (by the RCC or CCO) and transferred to the central laboratory for analysis (see Section 4.2.1) and for long-term frozen storage. Full details of sample collection, transport, storage and analysis are provided in a separate SOP.

2.6.4.3 Consent approval for unspecified analyses on blood and urine samples
Sample tubes will be labelled with a unique Sample ID which will be linked to the participant and the study visit using the study computer-based data entry system (i.e. samples will be pseudonymised). Outside the study clinic, staff involved in the transport, storage and analysis of these samples will have no means of linking tubes to an identifiable participant. Consent for protocol-specified analyses will be included in the main consent form. In addition, all participants will be asked if they would provide Supplementary Consent to allow
samples that have been collected for central laboratory analyses to be retained and used for unspecified analyses in the future. Similarly, Supplementary Consent will be sought to permit genetic material in the blood samples to be analysed. In all cases, participants will be free to opt in or out of any part of the Supplementary Consent without affecting their eligibility for the trial.

2.6.5 Administrative details

2.6.5.1 Source documents and archiving
Source documents for the study constitute the clinic visit records held in the study main database, results of protocol-mandated local laboratory blood and urine analyses, the additional information obtained on reported adverse events that are relevant to the outcome measures (see Section 3.7), death certificates, and drug supply records. These will be retained for at least 25 years from the completion of the study. Boehringer Ingelheim and regulatory agencies will have the right to commission a confidential audit of such records in the CCO, RCCs, and LCCs provided this does not result in unblinding while the study is in progress.

2.6.5.2 Funding
This study was initiated by CTSU, University of Oxford and developed as an academic collaboration with clinical scientists at Boehringer Ingelheim. Boehringer Ingelheim is the sponsor, and will perform regulatory submissions and interactions. It will also provide funding and packaged study medication (empagliflozin and matching placebo) for the study. Boehringer Ingelheim has delegated other roles to the University of Oxford, which is responsible for leading the trial scientifically and methodologically worldwide, including its conduct and statistical analysis. It is intended that the study will be conducted in the US in collaboration with independent scientists from the Duke Clinical Research Institute, Duke University. Data will be collected and analysed independently from the source of funding.

2.6.5.3 Indemnity
Boehringer Ingelheim will, at all times, indemnify the study investigators and study staff from claims that may be made against them for any injury sustained by a study participant as a consequence of participation in the study in accordance with this protocol. The indemnity will be outlined in detail in the agreements between the CCO, RCCs and LCCs (and in a letter from Boehringer Ingelheim).

2.6.5.4 End of the within-trial period
When the minimum number of required study outcomes has accrued (see Section 2.4.1.2), or the DMC advises the trial should be stopped early, participants will be invited to Final Follow-up visits. This visit may occur earlier than their planned next 6-monthly visit. The end of the trial is then defined as the latest of the following two dates: 7 days after the last participant’s Final Follow-up visit, or the date of the last 4-week post-Final Follow-up blood draw.

2.6.5.5 Publications and reports
The Steering Committee (which includes representatives from University of Oxford, Duke University and Boehringer Ingelheim, as well as other individuals with relevant expertise) will be responsible for drafting the primary manuscript from the study and will establish a publication plan for secondary and supplementary analyses. In general, papers initiated by the Steering Committee (including the primary manuscript) will be written in the name of the Collaborative Group, with individual investigators named personally at the end of the report (or, to comply with journal requirements, in web-based material posted with the report). Draft copies of any manuscripts relating to the effects of empagliflozin from this trial will be
provided to Boehringer Ingelheim for review prior to publication but the decision to submit for publication will rest with the Steering Committee.

The Steering Committee will also institute a process by which proposals for additional publications (including from clinician scientists within Boehringer Ingelheim seeking to further evaluate the benefit-risk profile of empagliflozin and from independent external researchers) are considered by the Steering Committee before they begin. The Steering Committee will facilitate the use of the study data and approval will not be unreasonably withheld. However, the Steering Committee will need to be satisfied that any proposed publication is of high quality, honours the commitments made to the study participants in the consent documentation and ethical approvals, and is compliant with relevant legal and regulatory requirements (e.g. relating to data protection and privacy). The Steering Committee will have the right to review and comment on any draft manuscripts prior to publication.

2.6.5.6 Substudies
Proposals for substudies must be approved by the Steering Committee before they begin. In considering such proposals, the Steering Committee will need to be satisfied that the proposed substudy is of a high quality, and that it will not compromise the main study in any way (e.g. by reducing the recruitment rate or compliance with study treatment or overuse of stored biological samples).
## FLOWCHART OF TRIAL ACTIVITIES

### PRE-SCREENING PHASE
- Identify potentially eligible individuals: age ≥18 years*; chronic kidney disease (i.e. CKD-EPI eGFR ≥20, <45 mL/min/1.73m² or eGFR ≥45, <90 mL/min/1.73m² with urinary albumin: creatinine ratio ≥200 mg/g [or, if not available, urinary protein: creatinine ratio ≥300 mg/g])
- Invite to attend Screening visit clinic appointment in local study clinic

### SCREENING VISIT (-8 to -12 WEEKS) AND PRE-RANDONIZATION RUN-IN PHASE
- Relevant details to confirm participants meet certain inclusion criteria collected
- Written informed consent sought from potentially eligible and willing individuals
- Relevant medical history and medication to assess eligibility recorded
- Blood pressure measured and recorded
- Blood sample for creatinine, liver transaminases and urine sample for albumin:creatinine (or protein:creatinine) ratio taken for local laboratory analysis. Pregnancy test required only in women of child-bearing potential if, after questioning, pregnancy is considered reasonably possible.
- Eligible participants asked to start single-blind placebo Run-in phase
- Randomization visit appointment scheduled for 8-12 weeks later
- Local Research Co-ordinator enters local laboratory results and those ineligible dropped out
- Local Investigators review results, confirm individualized standard of care including appropriate dose of RAS-inhibition (where indicated and tolerated) and management of other relevant co-morbidities and approve participation

### RANDOMIZATION VISIT (0 MONTHS)
- All SAEs during Run-in and full list of non-study medication recorded
- Blood pressure measured and recorded
- Check of compliance, eligibility and consent
- Assessment of other medical information (including history of peripheral arterial disease, amputation, heart failure, NYHA class & health related quality of life measured using the EQ5D-5L questionnaire)
- Height, weight, and hip and waist circumference recorded
- Blood samples taken for local laboratory analysis (creatinine/potassium/liver transaminases/bilirubin and haematocrit) and for central analyses (creatinine/HbA1c/NT-proBNP) and frozen storage
- Urine collected for central analysis (albumin and creatinine) and frozen storage
- Randomization via computer-based system: allocated empagliflozin 10 mg daily or matching placebo
- First Follow-up visit appointment scheduled for 2 months’ time
- Participant’s doctor informed of participant’s randomization

### FOLLOW-UP VISITS AT 2 and 6 MONTHS, THEN 6-MONTHLY
- SAEs, AESIs, selected non-serious AEs, adherence, and changes to non-study medication recorded
- Reasons for stopping study treatments and date of stopping recorded (where relevant)
- Blood pressure and weight measured and recorded (waist and hip circumference at 18 months and Final Follow-up)
- Blood sample taken for local laboratory analysis of creatinine, potassium, liver transaminases, and bilirubin at each visit in all participants and, in a 20% subset, haematocrit/ haemoglobin/ sodium/ phosphate/ corrected calcium at 18 months
- Central analysis for creatinine at each visit; HbA1c also measured in central samples in all participants at 2 and 18 months, and at the Final Follow-up (when scheduled study treatment ends)
- Urine samples taken for central analysis and storage for future assays in all participants at 2 and 18 months, and at the Final Follow-up
- Follow-up randomization treatment pack issued and assessment of compliance
- Assessment of quality of life (by EQ5D-5L questionnaire) at 18 months and Final Follow-up visit only
- Extra local blood sample taken 4 weeks after Final Follow-up for local laboratory analysis of creatinine in a 20% subset

### OVERSIGHT AND MONITORING OF SAFETY AND EFFICACY
- LLI will meet regularly with LCC clinic staff to review study progress, including the delegation of duties log and approve listings of reported adverse events
- Central monitoring of laboratory results & adverse events by CCO clinicians (+ Early Recall if needed)
- Further details on relevant outcomes sought from participant’s doctor and other sources (e.g. registries and electronic healthcare records) as required to support outcome adjudication
- Relevant events confirmed centrally by clinicians blind to treatment allocation

* Or “full age” as required by local regulation (e.g. 20 years in Japan)
3.1 **Eligibility for the Study**

Consenting individuals are eligible for randomization if:

(i) Age is ≥18 years; 
(ii) There is evidence of chronic kidney disease at risk of kidney disease progression (see Section 3.1.1); 
(iii) A local Investigator judges that the participant neither requires empagliflozin (or any other SGLT-2 or SGLT-1/2 inhibitor), nor that such treatment is inappropriate; and 
(iv) None of the exclusion criteria apply (see Section 3.1.2).

Participants will be treated with appropriate doses of single agent RAS-inhibition with either ACEi or ARB unless such treatment is either not tolerated or not indicated (see Section 3.3.4).

No potential participant currently being treated with empagliflozin (or other SGLT-2 or SGLT-1/2 inhibitor) should be taken off this therapy to meet the eligibility criteria.

3.1.1 **Inclusion criteria**

Evidence of progressive CKD at risk of kidney disease progression is defined on the basis of local laboratory results recorded at least 3 months before and at the time of the Screening visit, and requires that:

(a) CKD-EPI eGFR ≥20 <45 mL/min/1.73m²; or 
(b) CKD-EPI eGFR ≥45 <90 mL/min/1.73m² with urinary albumin:creatinine ratio ≥200 mg/g (or protein:creatinine ratio ≥300 mg/g)

Note: the number of participants with or without diabetes mellitus (of any type) will be at least one-third of each, and the number of participants with an eGFR >45 mL/min/1.73m² limited to about one-third. The Steering Committee will monitor these proportions and will limit recruitment of particular categories of participant in whom sufficient numbers have already been screened or randomized.

3.1.2 **Exclusion criteria**

None of the following must be fulfilled:

(i) Currently receiving SGLT-2 or SGLT-1/2 inhibitor; 
(ii) Diabetes mellitus type 2 and prior atherosclerotic cardiovascular disease with an eGFR >60 mL/min/1.73m² at Screening; 
(iii) Receiving combined ACEi and ARB treatment; 
(iv) Maintenance dialysis, functioning kidney transplant, or scheduled living donor transplant; 
(v) Polycystic kidney disease; 
(vi) Previous or scheduled bariatric surgery; 
(vii) Ketoacidosis in the past 5 years; 
(viii) Symptomatic hypotension, or systolic blood pressure <90 or >180 mmHg at Screening; 
(ix) ALT or AST >3x ULN at Screening; 
(x) Hypersensitivity to empagliflozin or other SGLT-2 inhibitor;

---

Note: 

- Or “full age” as required by local regulation (e.g. 20 years in Japan). 
- Based on self-reports at Screening and Randomization visits. 
- Myocardial infarction, angina, stroke or peripheral arterial disease (including lower limb amputation) 
- Or renin-inhibitor combined with ACEi or ARB.
(xi) Any intravenous immunosuppression therapy in last 3 months; or anyone currently on >45 mg prednisolone (or equivalent);
(xii) Use of an investigational medicinal product in the 30 days prior to Screening visit;
(xiii) Known to be poorly compliant with clinic visits or prescribed medication;
(xiv) Medical history that might limit the individual’s ability to take trial treatments for the duration of the study (e.g. severe respiratory disease; history of cancer or evidence of spread within last 4 years, other than non-melanoma skin cancer; or recent history of alcohol or substance misuse);
(xv) Current pregnancy, lactation or women of childbearing potential (WOCBP), unless using highly-effective contraception;
(xvi) Type 1 diabetes mellitus.

In addition, individuals will be excluded at the Randomization visit if the participant:
(i) Does not adhere to Run-in treatment;
(ii) Is no longer willing to be randomized and followed for at least 3 years;
(iii) Is considered by a local investigator not to be suitable for randomization (see Section 3.3.4); or
(iv) Experiences ketoacidosis, heart attack, stroke, or hospitalization for heart failure, or hospitalization for urinary tract infection or acute kidney injury during Run-in.

Note that individuals who do not fulfil one or more inclusion criteria, or who fulfil one or more exclusion criteria, may be re-screened and later become eligible.

3.2 IDENTIFICATION AND INVITATION
3.2.1 Identification and invitation of potentially eligible participants

Extensive pre-screening efforts will be made to identify large numbers of potential participants at each LCC. The exact methods will vary by centre and by country, and in all cases will be subject to appropriate institutional review board approval and compliance with data privacy regulations. In general, potentially eligible participants (based on age, blood and urine results) will be identified from clinical records (including electronic health care records) and contacted to seek their provisional agreement to attend a Screening visit. Potential participants will be given information about the study.

3.3 SCREENING VISIT AND PRE-RANDOMIZATION RUN-IN
3.3.1 Assessment of relevant medical history and eligibility

LCC clinic staff will recheck basic inclusion criteria are met (e.g. age and the blood/urine results used to identify potential participants) then take written informed consent.

3.3.2 Written consent

Individuals who appear initially to be eligible will have the study explained to them by the clinic staff, using the Participant Information Leaflet and Consent Form as a basis for discussion. Where relevant, supplementary Consent will also be sought (see Section 2.6.4.3). Each individual will have an opportunity to initiate discussion, and have time to think about their participation in the study, perhaps after discussing it with their family or a local doctor. Individuals who choose to do this will be asked to attend a repeat Screening visit.

---

*Based on self-reports at Screening and Randomization visits.

*Highly effective methods of contraception include implants, injectables, combined oral contraceptives (the participant must have been on a stable dose for at least 3 months prior to entering the trial), intrauterine device, vasectomised partner, or true sexual abstinence (when this is the preferred and usual lifestyle of the patient and does not include periodic abstinence [e.g. calendar, ovulation, symptothermal or post-ovulation methods]). Use of such methods must be maintained throughout the trial and for 7 days after the end of the trial.*
within a few weeks. Attendees will be discouraged from participating if it is thought unlikely that they would be willing and able to continue attending Follow-up visits for at least 3 years.

3.3.3 Confirmation of eligibility and collection of blood and urine samples

After providing written consent, blood/urine test results will be recorded. Other medical history (including primary renal diagnosis and other co-morbidity), non-study medication, blood pressure and other factors pertinent to eligibility will be obtained directly from participants (rather than from hospital record review) and recorded directly into the Screening Form. These inclusion and exclusion criteria will be checked with the assistance of the study computer-based system.

A non-fasting blood sample will be taken for local analysis of creatinine and liver transaminases (AST or ALT), and a urine sample will be taken for local analysis of urinary albumin:creatinine ratio (or, if albuminuria measurement unavailable in local laboratory, protein:creatinine ratio). The LCC clinic staff will issue a 15 week supply of placebo tablets to eligible participants.

WOCBP, defined as women less than 55 years of age unless surgically sterile or with history of a postmenopausal state, will be requested to use highly effective methods of contraception. A pregnancy test will be offered if, after questioning about recent menses and regularity of menstrual cycle, pregnancy is considered reasonably possible (or if a pregnancy test is required by local regulation).

Participants with diabetes will be educated about the risks of diabetic ketoacidosis and the actions they should take if they suspect it, and will be provided with a specific information card (see Section 3.5.6).

An appointment will be made for the Randomization visit in 8-12 weeks. The participant’s doctor(s) will be informed that the participant has entered Run-in.

Following the Screening visit, the locally analysed blood and urine results will be recorded onto the study computer-based system, which will provide another assessment of eligibility (see Section 3.1). If these results indicate that the participant is not eligible for the trial, they may be repeated once if in the opinion of a Local Investigator they were spurious, otherwise the participant will be withdrawn from the Run-in period and asked to stop and return all placebo Run-in medication.

3.3.4 Review of eligibility and renin-angiotensin system inhibition by a Local Investigator

During Run-in, the LLI (or authorised delegate) will be given a description of the participant’s medical history (including primary renal diagnosis), single agent RAS-inhibition treatment and blood and urine results all based on the Screening visit, and asked to indicate whether, in their view, these results (or any other factor) make the participant unsuitable for entry into the randomized phase of the study. Additionally, participants should be randomized only if a Local Investigator judges that the participant does not require empagliflozin (or any other SGLT-2 or SGLT-1/2 inhibitor), and neither is such treatment inappropriate. No patient currently being treated with empagliflozin (or other SGLT-2 or SGLT-1/2 inhibitor) should be taken off this therapy to meet the eligibility criteria.

For eligible participants, the LLI (or authorized and medically qualified delegate) will also be asked to confirm that the participant is prescribed, in their opinion, an appropriate dose of
single agent RAS-inhibition (i.e. ACEi or ARB, but not both). Those participants for whom RAS inhibition is not considered indicated (e.g. due to concomitant medication or comorbidity), or who cannot tolerate RAS inhibition, will still be eligible to enter the trial, but the reason for not using RAS-inhibition will be documented. Those participants who, in the opinion of the LLI, need to start RAS inhibition or are not on an appropriate dose will be excluded from the study (but may be rescreened later, e.g. once established on an appropriate dose).

Additionally, throughout the study, the care of participants will remain the responsibility of their local doctors, who are asked to ensure appropriate and individualized care. This includes appropriate management of risk of kidney disease progression, risk of cardiovascular disease, and other conditions which are common in CKD (such as mineral-bone disorder, renal anaemia, metabolic acidosis). Modifiable risk factors include but are not limited to glycaemic control in participants with diabetes, blood pressure control, and treatment of dyslipidaemia. It is advised that this is conducted in the context of prevailing local, national or international guidance.

3.4 Randomization Visit (0 Months)
3.4.1 Final check of eligibility and compliance before randomization

For individuals who attend their Randomization Clinic appointment, study eligibility will be confirmed (see Section 3.1). The participant will also be asked if they have experienced any SAE or significant problems during the Run-in period. Information on other relevant factors will also be collected, such as prior history of urosepsis, heart failure and New York Heart Association (NYHA) functional classification, history of peripheral neuropathy, diabetic foot ulcer, lower limb infection or gangrene, smoking history and alcohol intake, and an assessment of health related quality of life is to be made (using the EQ5D-5L questionnaire). Details of all non-study treatments will be sought, compliance with Run-in treatment checked, and consent information checked. Blood pressure, height, weight, and hip and waist circumference will be measured. The participant’s willingness to take study medication and attend follow-up visits for at least 3 years will be confirmed. Details will be recorded directly onto the Randomization Form on the study computer-based system (which is designed to obtain complete information, assess eligibility, and to prompt appropriate actions).

3.4.1.1 Collection of blood and urine samples

Eligible participants will have a blood sample taken for local measurement of creatinine, potassium, liver function (ALT or AST, and bilirubin), and haemoglobin/haematocrit. Blood and urine samples will also be processed in preparation for subsequent transportation to the central laboratory (see Section 2.6.4).

3.4.2 Random allocation of study treatment

Eligible and consenting individuals will be allocated empagliflozin or matching placebo using a minimized randomization program on the study computer-based system (see Section 2.2.2).33 Participants will be allocated a numbered treatment pack containing a 7-month supply of one tablet daily of either active empagliflozin 10 mg or matching placebo.

The numbered treatment packs will be issued to the participant by the LCC clinic staff or their local hospital pharmacy. An appointment for the first post-randomization Follow-up visit will then be made by the study staff, with guidance from the study computer-based system. The participant’s doctor(s) will be informed that the participant has been randomized.
Following the Randomization visit, the locally analysed blood results will be recorded onto the study computer-based system by the LCC.

3.5 Follow-up Visits (2 and 6 months and then 6-monthly)

3.5.1 Recording adverse events and adherence to study treatment

Following randomization, all participants are scheduled to attend Follow-up visits at 2 and 6 months, and then 6-monthly until the end of the study.

At each visit, details of all hospital admissions and any other SAEs will be sought from participants, and questions will specifically be asked about SAEs due to urinary tract infection, genital infection, hyperkalaemia, acute kidney injury and dehydration. Information about new-onset of diabetes, gout, AESIs (i.e. liver injury, ketoacidosis and lower limb amputation), bone fractures, severe hypoglycaemia and symptomatic dehydration will also be recorded. The source of the information/data is the report from the participant (or where unavailable a relative or other doctor) entered directly into the electronic case report form. In this study, paper or electronic hospital notes are not routinely reviewed to identify AEs. Any SAE considered to be due to study treatment (i.e. a possible SSAR) is to be discussed as soon as possible with a RCC/CCO study clinician in order that additional information can be collected (see Section 2.5.1.3).

Key changes to non-study medication will be sought, and adherence to study treatment will be reviewed. Adherence will be assessed and documented by LCC clinic staff at every study visit by asking participants about missed doses and visual inspection of remaining tablets (a pill count will not be performed). The amount of study treatment taken since the last visit will be estimated and recorded as “most”, “some” or “little/none” (with further guidance on these categories provided in the LCC Clinic Manual). The LCC clinic staff will discuss any reasons for non-adherence with the participant (and with their LLI or with CCO clinical staff if necessary) and encourage the participant to take study treatment regularly whenever appropriate. For participants who discontinue study treatment, the reason for doing so will be sought.

Blood pressure and weight will be measured at each Follow-up visit. At the 18 month and the Final Follow-up visit, hip and waist circumference will be measured and health related quality of life (using EQ5D-5L questionnaire) will be assessed. Details are to be recorded directly onto the electronic Follow-up form on the study computer-based system.

Local Research Co-ordinators will be trained to ask participants to report any relevant AEs (related or not) occurring up to 7 days after their Final Follow-Up Visit directly to LCC clinic staff.

3.5.2 Collection of blood and urine samples

At each Follow-up visit, a non-fasting blood sample will be taken for local analysis for creatinine, potassium and liver function (ALT or AST, and bilirubin). Results are ideally entered onto the computer-based system within 2 working days. At 18 months of follow-up, a 20% subset of participants (e.g. UK participants) will also have haematocrit, haemoglobin, phosphate, sodium and corrected calcium measured locally.

Four weeks after the Final Follow-up visit, a subset of about 20% of participants (who have not started dialysis or have a functioning kidney transplant) will provide a further non-fasting blood sample for local analysis of creatinine (known as the 4-week post-Final Follow-up blood draw) and a urine sample for local analysis of urine albumin and creatinine.
At each scheduled follow-up visit a central blood sample will be collected. At the 2 and 18 month and Final Follow-up visits, urine samples will also be collected (see Section 2.6.4.2).

3.5.3 Issuing study treatment and arranging further appointments

Provided continuing study treatment remains appropriate, participants will be given a further 7-month supply of their randomly allocated study treatment (empagliflozin 10 mg or matching placebo), and any previously allocated treatment will be retrieved (except at the 2-month visit). An appointment will then be made for their next scheduled Follow-up visit.

3.5.4 Follow-up for randomized participants not attending study clinics

Follow-up information is to be collected from all study participants, irrespective of whether they continue to take study treatment, usually at routine Follow-up clinic visits, unless they withdraw consent (see Section 3.6.5). If, however, a participant becomes unwilling or unable to attend study clinic visits then LCC staff will telephone the participant (or, where appropriate, their relative or carer) at the time of each of their scheduled Follow-up appointments and complete the necessary Follow-up form on the study computer-based system. If monitoring of blood is no longer possible (e.g. because the participant no longer attends clinic visits and no other means of measuring creatinine/liver function can be arranged), then the participant will be asked to discontinue all study treatment and advised to see a local doctor. All efforts will be made to continue to follow-up such participants (as described above), and those being followed by telephone or other remote method will be encouraged to provide blood samples for central analysis at relevant time points. If this is not possible, then LCC or RCC staff will attempt to check a participant’s progress by interview or direct correspondence with the participant’s own local doctors or (where appropriate consent and approvals are in place) by reviewing available information on routine healthcare systems (including local blood result systems) and registries. (In the UK, for example, there are registries for treated ESKD, hospital admissions, cancers, and deaths.) Such information could also be used for long-term follow-up, alongside participant questionnaires administered by telephone, mail or electronically.

3.5.5 Monitoring of women of child bearing potential

Animal studies show that empagliflozin crosses the placenta during late gestation to a very limited extent, but it is considered preferable to avoid its use during pregnancy. WOCBP will therefore have to agree to use highly effective methods of contraception during the trial. At each visit, a pregnancy test will be offered if, after questioning about recent menses and regularity of menstrual cycle, pregnancy is considered reasonably possible (or if a pregnancy test is required by local regulation). LCC clinic staff will also reinforce the need for highly effective contraception at each visit. If a participant becomes pregnant during the trial, the trial medication will be stopped and the participant will be followed up until birth or termination of the pregnancy (see further details for reporting of pregnancy in Section 2.5.1.1).

3.5.6 Monitoring of people with diabetes mellitus

LCC clinic staff will receive training on the specific risk of ketoacidosis (which can present with lower than anticipated blood glucose levels in people with diabetes treated with SGLT-2 inhibitors) and will be asked to provide additional written information about ketoacidosis to participants with diabetes (e.g. a trial information card). Testing equipment and materials to detect blood ketones will be available to people with type 1 diabetes before Randomization.
3.5.7 Local Lead Investigator supervision

LLI will meet regularly with the other LCC staff to review study progress, the delegation of duties log and approve listings of reported adverse events. The RCC or CCO will be contacted if adverse event information needs to be refined.

3.6 CENTRAL MONITORING OF PARTICIPANT SAFETY, EARLY RECALL VISITS AND MODIFYING STUDY TREATMENT

3.6.1 Early Recall Visits

An Early Recall visit may be arranged for any participant who requires review outside their planned visit schedule. Examples of circumstances where this may be necessary include the assessment of abnormal values in safety blood results from routine Follow-up visits, or if symptoms of liver disease (e.g. icterus) develop between scheduled Follow-up visits, or an extra visit is required a few weeks after the Randomization Visit (e.g. if requested by local regulators or Local Investigator). As at routine study visits, the results of blood tests performed at Early Recall visits will be entered by LCC clinic staff into the study computer-based system (which is designed to prompt appropriate actions) and these results will be monitored centrally by clinical staff at the CCO and RCCs in accordance with the study procedures.

3.6.2 Monitoring liver function, potassium, creatinine and AESIs

CCO study clinicians will be responsible for reviewing local results on liver function, potassium and creatinine, and all reports of AESIs. They will advise on the need for (and timing of) Early Recall visits and whether study treatment should be stopped or restarted. In so doing, CCO study clinicians will collaborate with the LLI and other LCC clinic staff (or RCC in certain regions), as necessary, and will generally initiate contact if there have been results that fulfil the definition of liver injury or a 50% increase in creatinine since the preceding Follow-up visit. Management strategies include ascertainment of a more detailed clinical picture, additional investigations, more frequent study visits, or a lower threshold for stopping study treatment.

3.6.3 Modifying study treatment

If adverse events occur that are believed to be due to empagliflozin, including significant elevation of liver transaminases, the study treatments may be temporarily or permanently discontinued. The following events are also sufficient reason to discontinue the study empagliflozin or placebo:

- SAE considered likely to be due to the study treatment (i.e. SSAR, see Section 2.5.1.3)
- Kidney transplantation
- New reason to prescribe empagliflozin or another SGLT-2 or SGLT-1/2 inhibitor (e.g. a local doctor of the opinion that it should be included as part of the current standard of care for prevention of cardiovascular events); or new reason not to use an SGLT-2 inhibitor (e.g. local doctors may choose to stop study treatment on initiation of maintenance dialysis or after ketoacidosis)
- Pregnancy or suspected pregnancy
- At the request of the participant or their doctors (for whatever reason) or any other situation where continuing study treatment is not considered to be in the participant’s best interests by their own doctors or the study clinical team (including cessation of use of reliable contraception in WOCBP or use of high potency immunosuppression).
Whenever possible, the study computer-based system will prompt LCC clinic staff to consider whether there are specific reasons to discontinue or to restart study treatment (if appropriate, i.e. if reasons for discontinuation do not exist any longer). CCO study clinicians will provide advice if required.

3.6.4 Unblinding of study treatment

There are two main situations in which unblinding of the treatment allocation (empagliflozin or placebo) for an individual participant may be warranted:

- When knowledge of the treatment allocation could materially influence the immediate medical management (e.g. after overdose)
- When unblinding is necessary as part of Safety Reporting (see Section 2.5.1.4).

Urgent unblinding is available by contacting a CCO study clinician on a 24-hour basis via the CTSU Freefone telephone service. For the avoidance of doubt, if an investigator or local doctor requests the unblinded treatment allocation, it will be provided. All unblinding episodes are logged within the study computer-based system.

3.6.5 Withdrawal of consent

Participants may decide that they no longer wish to take study treatment or are no longer willing to attend study visits. LCCs may be able to help participants overcome problems associated with personal circumstances (e.g. provide transport support to attend clinics). These decisions are not considered to be withdrawals of consent, and appropriate procedures for dealing with them are described elsewhere in this protocol (e.g. for discontinuation of study treatment see Section 3.6.3 and for alternative methods of follow-up see Section 3.5.4). However, participants are free to withdraw consent for some or all aspects of the study at any time. In order to ensure that relevant safeguards are put in place to maintain the individual’s safety (e.g. if an important safety issue comes to light that might affect a participant who has previously withdrawn from the study) and to prevent a breach of the individual’s decision to withdraw (e.g. to prevent re-invitation of an individual who had previously withdrawn consent), the decision to withdraw should ideally be put in writing and a copy maintained at the LCC (with key data items being recorded on the study computer-based system). This written information should specify which aspect(s) of the study consent is being withdrawn: for example, direct contact from study staff; collection of information from a relative or friend; collection of information from local doctors or routine data sources; or the storage and analysis of samples for protocol-specified future unspecified assays. (In accordance with regulatory guidance, data that have already been collected and incorporated into the study database, including the results of laboratory assays, will continue to be processed.)

3.7 Confirmation and Verification of Study Outcomes (“Adjudication”)

Outcomes (and components) purely based on laboratory values (e.g. sustained \( \geq 40\% \) decline in eGFR,) will not be adjudicated and analyses will emphasize the results of measurements made at central laboratories. Wherever possible, eGFR will be calculated using centrally measured serum creatinine (with local results substituted if central results are unavailable). eGFR will be calculated using the CKD-EPI creatinine formula.\(^{40}\)

Receipt of a kidney transplant or initiation of maintenance dialysis will also not be adjudicated. Instead, LCC reports will be cross-checked by the CCO with information at
subsequent follow-up visits or (where available) with additional medical information collected for adjudication of deaths.

Additional medical information will be sought for AEs that undergo adjudication. In general, these will be limited to all deaths and events initially reported as hospitalization for heart failure, myocardial infarction, stroke, liver injury, ketoacidosis, lower limb amputation and acute kidney injury. Other events may be added to the adjudication list if considered necessary to ensure a reliable assessment of the clinical effects (and particularly safety) of empagliflozin. Most hospitalizations will not be adjudicated and so analyses of hospitalizations will mainly be based on LCC reports.

Relevant information needed for adjudication may come from the records held at the LCCs and other hospitals, from participant’s own doctors, or from electronic sources and registries. In some cases it may be necessary to obtain information that predates randomization into the study. A central panel of clinicians based at, or overseen by, the CCO will provide the adjudication. Review, processing and adjudication of AEs will be conducted in accordance with the study SOPs and will be blinded to study treatment allocation (empagliflozin or placebo). The relevant SOP will detail a quality control process where the first events adjudicated by each adjudicator and a random subsample thereafter (about 5%) will be reviewed by a second adjudicator (blind to original adjudication).

3.8 CITED REFERENCES


4.1 Appendix 1: Organisational Structure and Responsibilities for Study Design and Conduct

Boehringer Ingelheim
Boehringer Ingelheim has delegated certain responsibilities to the independent Principal Investigators and CCO at the University of Oxford, and to the Steering Committee. Boehringer Ingelheim remains fully responsible for:

- Provision of study funding
- Provision and distribution (but not allocation) of manufactured and labelled study drug
- Regulatory submissions and interactions (with support from the Principal Investigators)
- Auditing of investigational sites, facilities, study setup, study processes, etc. as per the Audit Plan.

Responsibility for oversight of the quality and integrity of the trial data remains with Boehringer Ingelheim.

Principal Investigators
The Principal Investigators have overall responsibility for:

- Design of the study (in collaboration with Boehringer Ingelheim)
- Preparation of the Protocol and subsequent revisions
- Managing the CCO
- Development of computer-based systems and study SOPs.

Steering Committee
The Steering Committee is responsible for:

- Agreeing the Data Analysis Plans
- Reviewing progress of the study and, if necessary, suggesting and agreeing changes to the Protocol
- Reviewing new scientific evidence that may be of relevance
- Drafting, review and approval of study main publication(s)
- Review and approval of proposals for subsequent analyses and publications
- Approval of substudy proposals
- Reviewing study quality and risk management approaches, and ensuring that the focus is always on issues that have (or the potential to have) a substantial impact on the safety of the study participants or the reliability of the study results
- Monitoring participant characteristics and limiting recruitment of particular categories of participant when sufficient numbers have already entered the trial.

Data Monitoring Committee
The independent Data Monitoring Committee is responsible for:

- Reviewing unblinded interim data according to the schedule outlined in the Protocol
- Advising the Steering Committee if, in their view, the randomized data provide evidence that may warrant early termination of all or part of the study for either efficacy or safety
- Review of the formal interim analyses (see Section 2.5.2.2).

**Central Coordinating Office**
The CCO is responsible for the overall coordination of the Study, including:

- Study planning and organisation of Steering Committee meetings
- Agreement of each regional recruitment plan (including countries, number of LCCs, number of participants, and timelines)
- Contractual issues with RCCs and budget administration
- Co-ordination of Ethics Committee applications
- Supporting Boehringer Ingelheim in their interactions with regulatory authorities and other outside agencies as appropriate
- Design, implementation and maintenance of computer-based systems for the study (including CCO/RCC computer-based system for administration and study computer-based system for direct data entry)
- Provision of study materials to RCCs and LCCs, and provision of IT support to RCCs
- Monitoring of drug supply in liaison with Boehringer Ingelheim (who will be responsible for drug distribution to each LCC)
- Central laboratory assay and long-term storage of blood and urine samples
- Monitoring of overall progress of the study, with a focus on critical-to-quality factors
- Clinical safety monitoring, including reporting of SSARs to the Chair of the Data Monitoring Committee and to Boehringer Ingelheim
- Responding to technical, medical, data and administrative queries from the RCCs
- Manage data queries and data changes (with a clear audit trail)
- Management of outcome adjudication
- Liaison with the Data Monitoring Committee.

**Regional Coordinating Centres**
Each RCC is responsible, under the direction of its Regional Coordinator, for:

- Identification of potential LCCs and agreement of their recruitment plans (including number of participants and timelines)
- Contractual issues with LCCs and regional budget administration
- Obtaining any central Ethics Committee approval (where appropriate) and assisting LCCs with local Ethics Committee applications
- Training of LCC staff and assistants
- Distribution of study materials to LCCs
- Responding to technical, medical and administrative queries from the LCCs
- Perform LCC on-site monitoring visits by trained study monitors
- “Process” monitoring of LCCs by responding to regular or occasional reports on regional progress prepared by the CCO
- Ensuring appropriate follow-up of abnormal safety blood results
- Collection and initial processing of relevant documentation to confirm reported events in line with study SOPs
- Collection and short-term storage of blood and urine samples from LCCs, and subsequent transport of them to the CCO
- Organisation of meetings of collaborators within the region
- Entering data entry errors reported by LCCs
- Supporting Boehringer Ingelheim in their interactions with regulatory authorities as appropriate
• Ensuring that trial-related activities are performed according to local regulations.

Local Clinical Centres
The LCC lead investigator and LCC staff are responsible for:

• Meeting regularly as a team to review study progress locally, the delegation of duties log and for Local Investigators to review and approve listings of locally reported adverse events (i.e. provide LLI oversight)
• Obtaining local Ethics Committee approval were necessary (aided by the RCC)
• Obtaining local management approval where necessary
• Performing trial-related activities according to local regulations
• Provision of adequate clinic space and access to appropriate systems for the identification of potentially eligible individuals
• Conducting clinic procedures: managing and distributing study drugs (in conjunction, if required, with the hospital pharmacy), and maintaining relevant study equipment in accordance with the Protocol and SOPs
• Ensuring adequate local laboratory facilities for safety monitoring and, if necessary, processing and temporarily storing samples for central analysis
• Reviewing Screening Form data, confirm appropriate dose of RAS-inhibition (where relevant), confirm no reasons to prescribe or not prescribe empagliflozin (or other SGLT-2 or SGLT-1/-2 inhibitor), and approving participants for randomization (Local Investigators only)
• Providing individualized care, including management of cardiovascular risk factors and other existing comorbidities (e.g. hypertension, diabetes) according to relevant guidelines
• Dealing with routine enquiries from participants and their families in collaboration with the RCC where necessary
• Obtaining clinical information when requested to confirm potential primary and secondary, tertiary and safety study outcomes
• Informing the RCC or CCO of any possible data entry errors.
## 4.2 APPENDIX 2: VISIT SCHEDULE AND PROCEDURES

### 4.2.1 Clinic procedures

<table>
<thead>
<tr>
<th>Task</th>
<th>Activity</th>
<th>Registration - 12 to -8 weeks</th>
<th>Screening 0 months</th>
<th>Randomization 2 months</th>
<th>In-trial follow-up 6 months</th>
<th>6 monthly visits</th>
<th>Final visit**</th>
</tr>
</thead>
<tbody>
<tr>
<td>Demographics</td>
<td>Record contact details</td>
<td>X</td>
<td>check</td>
<td>check</td>
<td>check</td>
<td>check</td>
<td>check</td>
</tr>
<tr>
<td>Medical history &amp; eligibility assessment</td>
<td>Relevant medical history (incl. inclusion criteria &amp; an dose of RAS inhibitor)</td>
<td>X</td>
<td>X</td>
<td>check</td>
<td>check</td>
<td>check</td>
<td>check</td>
</tr>
<tr>
<td></td>
<td>Exclusion criteria (incl. relevant non-study medication)</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>check</td>
<td>check</td>
</tr>
<tr>
<td></td>
<td>Other information (smoking, alcohol)</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>check</td>
<td>check</td>
</tr>
<tr>
<td></td>
<td>Use of non-study medication</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>check</td>
<td>check</td>
</tr>
<tr>
<td>Consent</td>
<td>Obtain consent</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>check</td>
<td>check</td>
</tr>
<tr>
<td></td>
<td>Confirm consent</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>check</td>
<td>check</td>
</tr>
<tr>
<td>Safety &amp; outcomes reporting</td>
<td>Adverse events (incl. Suspected Serious Adverse Reactions)</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td></td>
<td>Self-reported compliance</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td></td>
<td>Reasons for stopping study treatment (incl. SAEs, non-serious adverse events, other reasons)</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>check</td>
<td>check</td>
</tr>
<tr>
<td></td>
<td>Remote follow-up using routine data sources and/or participant surveys*</td>
<td>(X)*</td>
<td>X</td>
<td>X</td>
<td>(X)*</td>
<td>(X)*</td>
<td>(X)*</td>
</tr>
<tr>
<td></td>
<td>Quality of life (by EQ5D-SL)</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>18 month only</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physical measurements</td>
<td>Blood pressure</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td></td>
<td>Height</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td></td>
<td>Weight</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td></td>
<td>Hip &amp; waist circumference</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Local laboratory assessments</td>
<td>Creatinine and liver function tests (transaminases and bilirubin)</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td></td>
<td>Potassium</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td></td>
<td>Haematocrit, haemoglobin</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td></td>
<td>Sodium, corrected calcium, phosphate (in about a 20% subset)</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td></td>
<td>Urinary albumin and creatinine</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Central sample collection</td>
<td>Blood samples for central analysis of creatinine &amp; storage****</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td></td>
<td>Urine for central analysis of albumin &amp; creatinine, and storage</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Randomization &amp; study treatment handling</td>
<td>Issue placebo</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td></td>
<td>Randomize eligible &amp; willing participants</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td></td>
<td>Issue randomized treatment (empagliflozin 10 mg or placebo; 210 day supply)</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td></td>
<td>Retrieve unused treatment</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Appointment management &amp; advice</td>
<td>Create appointment</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td></td>
<td>Provide advice</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
</tbody>
</table>

* Remote follow-up may be used for some participants who are unwilling or unable to attend study visits, and for all surviving participants for several years after the final visit. ** Additional local blood creatinine and urine albumin:creatinine ratio measurement 4 weeks after final follow-up (~20% subset). Final follow-up timing is determined by the Steering Committee in response to numbers of events & DMC recommendations. *** If pregnancy reasonably possible as indicated by participant’s history (or if required by local regulation). **** NT-pro BNP measured at 0 months and HbA1c measured at 0, 2, 18 months and final visit.
4.3 APPENDIX 3: STUDY ADDRESSES

Sponsor
Boehringer Ingelheim International GmbH
Binger Strasse 173, 55216 Ingelheim, Germany

Central Coordinating Office and Wolfson Laboratories
Clinical Trial Service Unit and Epidemiological Studies Unit, Richard Doll Building,
Old Road Campus, Roosevelt Drive, Oxford OX3 7LF, UK
Tel: +44(0)1865 743868; E-mail: cco.empakidney@ndph.ox.ac.uk
5.1 Version History

EDMS #5434

<table>
<thead>
<tr>
<th>Version</th>
<th>Version date</th>
<th>Summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.0</td>
<td>8th January 2018</td>
<td>Version 1.0 finalized</td>
</tr>
<tr>
<td>1.1</td>
<td>8th January 2018</td>
<td>Footnote update</td>
</tr>
<tr>
<td>1.2</td>
<td>25th January 2018</td>
<td>Formal interim analysis update</td>
</tr>
<tr>
<td>1.3</td>
<td>26th March 2018</td>
<td>Update following MHRA review</td>
</tr>
<tr>
<td>1.4</td>
<td>25th April 2018</td>
<td>Update following FDA review of formal interim analysis</td>
</tr>
<tr>
<td>2.0</td>
<td>13th January 2020</td>
<td>Recruitment target increase to 6000 participants; exclusion of further participation from people with type 1 diabetes after introduction of a cap; clarification on the subdivisions of cardiovascular death; reducing tertiary subgroup analyses solely to the primary outcome and highlighting the subgroups of key interest; section 3.1.2 exclusion criterion (ix) modified; substituting local creatinine results when central creatinine results are missing; and clarification in table 4.2.1 that Hb/Hct is measured in all participants at randomization (to be consistent with the protocol text in section 3.4.1.1)</td>
</tr>
</tbody>
</table>